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Globally, cervical cancer takes the lives of more than 2,50,000 women each 
year, particularly in under-resourced areas of low-, middle-, and high-income 
countries. Options for cancer control and treatment have reached a point that there 
are interventions for control that could be adopted for virtually every resource and 
demographic situation. Emerging evidence demonstrates that targeting the tumor 
proteasome is a promising strategy for cancer therapy. Natural products with 
proteasome-inhibitory effects, such as green tea polyphenol (-)-epigallocatechin-3-
gallate (EGCG), soy isoflavone genistein, and the spice turmeric compound 
curcumin, have been studied alone and in combination with traditional 
chemotherapy and radiotherapy against various cancers. As a variety of 
antioxidants and chemopreventive agents are cytotoxic to cancer cells, thus, there 
is also interest in developing these natural compounds as potential 
chemopreventive agents. 
As the active role-played by reactive oxygen species (ROS) in the cervical 
cancer is well established, thus an attempt was made in the present study to probe 
natural compounds having antioxidant properties in arresting ROS in cancer cells. 
Various workers on cervical cancer HeLa cell lines have extensively carried out 
such a study, but no or little work has been done on cervical cancer monocytes. 
Thus, comparative efficacy of natural antioxidants was carried out on cervical 
cancer monocytes versus HeLa cell lines. Thus, in the present study, EGCG - a 
natural antioxidant and anti-mutagenic polyphenolic agent was employed to 
explore the comparative potential chemopreventive mechanism in cervical cancer 
monocytes versus cervical cancer cell lines i.e. HeLa cell lines. 
The most striking finding of the present study is the model system involving 
monocytes and biopsies from cervical cancer patients showed high magnitude anti-
inflammatory as well as apoptotic effect of EGCG (0-100 |ag/ml), while on the 
other hand, EGCG (0-100 ^g/ml) exerted high magnitude anti-inflammatory but 
low apoptotic effect on HeLa cell lines. 
Glutathione directly reacts with ROS, and GPx catalyzes the removal of 
hydrogen peroxide. Decrease in GPx activity indicates impairment of hydrogen 
peroxide-neutralizing mechanisms. In the present study, a decline in GPx activity 
was observed in cervical cancer monocytes and cervical HeLa cells that were 
untreated or treated either with H2O2 thereby correlating with earlier reports that 
substantial amounts of ROS are being generated in cancerous cells due to cellular 
activation. Enhancement of GPx activity in cervical cancer monocytes and cervical 
HeLa cell cultures after addition of NAC, a precursor of in vivo antioxidant 
glutathione, indicates reversal of impaired neutralizing mechanisms. Surprisingly, 
here slightly augmented GPx activity was observed when EGCG was co-cultured 
instead of NAC, indicating EGCG to be an effective natural antioxidant combating 
ROS, generated as a consequence of cellular activation in cancerous cell. Thus, our 
study shows enhanced GPx activity by EGCG, which correlated inversely with the 
downregulation of TNF-alpha, IL-1 and IL-6 protein expressions and ROS in 
cervical cancerous cells. 
Although the chemopreventive effect of EGCG has been extensively studied 
by a number of workers in cancerous cell lines, but its apoptotic effect and 
mechanism in biopsies and monocytes of cervical cancer patients still remains to 
be properly understood. Thus, in the present study, we show the mechanism of 
EGCG mediated apoptosis in monocytes of cervical cancer patients, which 
involved activation of caspase-3, the executor of apoptosis and cleavage of PAR? -
a specific marker of apoptosis as well as suppression of IL-6. EGCG was highly 
effective in inhibiting the viability of cervical cancer monocytes by PARP cleavage 
in response to activation of caspase-3. This resulted in the loss of normal PARP 
ftmction, which irreversibly commits the cell to die. 
Our present study demonstrated the activities of caspase-3, caspase-8 and 
caspase-9 in cervical cancer monocytes were activated by EGCG, indicating that 
both death receptor-related apoptotic pathway and the mitochondria-related 
pathway were activated. On the contrary, suppression or reduction in cell viability 
was inhibited by inhibitors of caspase-3, 8 and 9 namely Z-VAD-FMK, Z-IETD-
FMK and Z-LEHD-FMK respectively, which specifically blocked PARP cleavage. 
We further observed that either specific caspase-8 or caspase-3 inhibitor 
blocked the EGCG-induced apoptosis by an appreciably high magnitude, whereas 
the caspase-9 inhibitor only partially inhibited it. This implies that apoptosis 
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induced by EGCG in cervical cancer monocytes were initiated by a pathway 
involving the activation of caspase-8, leading to the activation of caspase-3 and the 
cleavage of PARP. The activation of caspase-9 is probably a secondary 
consequence of the activation of caspase-8 through the cross communication 
between the two apoptotic pathways. 
Cytosmears from non-neoplastic ectocervical biopsy cultures with EGCG 
also showed only keratinization promoting effects of EGCG and no apoptotic cells 
could be seen. On the contrary^ cytosmears from cervical cancer biopsy cultured 
with EGCG showed distinguished nuclear condensation and rounded contours with 
deep eosinophilia of cell cytoplasm, thereby indicating for EGCG-induced 
apoptotic. Histopathological sections from EGCG treated test samples also showed 
evidences of apoptosis, showing one apoptotic cell per 2-3 high power fields to 
more than one dispersed apoptotic cells in a single high power field. Occasionally, 
apoptotic cells were seen in groups implying foci of apoptotic changes. 
Next, we also report suppression of high levels of IL-6 in cultures of cervical 
cancer monocytes by EGCG to be dose-dependent. In accordance with its potential 
role in cancer progression, various types of cancer show elevated level of IL-6, and 
that, the strong ability of malignant cells to escape immune surveillance is a well 
known phenomenon. The anti-tumor immune response has been reported to be 
regulated by several factors, which includes cytokines produced by tumor and other 
cells of tumor stroma. It seems likely that the local cytokine microenvironment, 
acting on tumor cell or on the adjacent cells, can either block or facilitate tumor 
growth, and that proinflammatory cytokines strongly influence the immunologic 
state. 
Treatment with EGCG increased the proportion of cells in the Gi phase of 
the cell cycle and induced apoptosis. The results in the present study indicated 
EGCG to decrease the anti-apoptotic Bcl-2 protein expression, and activation of 
Caspase-3, 8 and 9, suggesting that EGCG induces apoptosis via a both cellular as 
well as mitochondrial pathway, although ths major pathway was oe-Uular. The 
observations made in the present study demonstrate that EGCG, a major 
component of green tea, possesses cervical cancer cell growth inhibitory 
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properties. It is likely that EGCG inhibits cancer cell growth through many 
different regulatory pathways, along with apoptosis and cell cycle arrest. The 
results of the present study are consistent with EGCG inhibiting cell growth and 
inducing apoptosis in cervical cancer biopsies and HeLa cell lines. The cytotoxic 
properties of EGCG seemed to be more effective against cervical cancer 
monocytes than HeLa cells. At this time, there is no explanation for these 
differences and more experiments are needed for further analysis. PARP-cleavage 
and FITC-Annexin assays in the present study clearly confirmed apoptosis 
induction in EGCG-treated cervical cancer cells. EGCG-induced apoptotic death in 
cervical cancer monocytes was mediated in part by activation of caspase-3. 
In summary, EGCG, a natural antioxidant, is a potent inducer of apoptosis in 
monocytes, biopsies of cervical cancer patients as well as HeLa cell lines, and that, 
induction of EGCG-mediated apoptosis involved activation of caspase-3 / CPP32, 
caspase-8 and caspase-9 as well as IL-6 suppression. The apoptotic as well as anti-
inflammatory / anti-proliferative effects of EGCG was more prominent in cervical 
cancer monocytes than in HeLa cell lines. Why EGCG is more effective in cervical 
cancer monocytes than in HeLa cell lines warrants further in-depth investigation. It 
is hoped that in view of the above aspects, whether EGCG can be promising 
candidate for the chemo-prevention of cervical cancer might be an interesting topic 
for further investigation. 
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In 1974, the Government of United Sates declared a "war on cancer" with the 
hope and anticipation that death from cancer be greatly reduced by the end of century. 
In spite of advances in cancer research and treatment, it still remained a major global 
health issue. According to American Cancer Society (ACS) on cancer statistics, 
cancer of the lung, prostrate, colon, rectum continues to be most common causes of 
cancer deaths (Jemal et al., 2002). 
Cancer is the leading cause of the death in the world and second in the United 
States, with one out of four deaths being cancer related World Cancer Research 
Fund/American Institute for Cancer Research (WCRF/AICR, 1997). More than 
1 million new cases of cancer and over 500,000 deaths occur each year in the U.S. 
due to cancer (Breslow, 1997). According to the American Cancer Society, in 2006 
an estimated 1,399,790 males and females in the United States were diagnosed with 
cancer (American Cancer Society, 2006) Moreover, It is projected that 14.7 miUion 
people globally will be diagnosed with cancer by the year 2020 (WCRF/AICR, 1997). 
Carcinogenesis is a complex, multi-step process in which signal transduction 
pathway involved in various normal cellular physiology are qualitatively or 
quantitatively altered (Vogelstein and Kinzler, 1993). Under normal conditions, these 
tightly controlled excitatory or inhibitory pathways regulate cellular functions like 
cell division, differentiation and senescence. Cancer is a group of diseases 
characterized by uncontrolled growth and proliferation of abnormal cells causing a 
total loss of cell function (American Cancer Society, 1998). Cancer was considered to 
be an unpredictable disease because treatments, even aggressive invasive procedures, 
often come with unpredictable outcome and reoccurrence (Gerster, 1993) For this 
reason it is important to emphasize the implications of education to prevent cancer. 
Cancer is the result of both genetic and environmental factors, which may act together 
or in sequence to initiate carcinogenesis (American Cancer Society, 1998). In 
addition to elucidating some of the genetic and environmental causes of cancer, 
currently researchers has also engaged to uncover the mechanisms by which 
carcinogenesis occurs. 
In this era of modernization and technology, large number of chemicals enters 
into our environment through occupational exposure, automobiles exhaust, pesticides, 
industrial wastes and contamination of food and water. These chemicals exist in the 
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environment in a relatively stable condition until taken in by an exposed individual 
and activated. Thus, these chemicals appear to pose a great concern and threat to 
mankind. Polycyclic aromatic hydrocarbon (PAH), nitrosamine, mycotoxins, 
pesticides and metallic contaminants such as arsenic and cadmium are some of 
xenobiotics that can enter in our food chain during processing, storage, preservation 
and cooking. According to International Agency for Research on Cancer (lARC), 
now there are about 88 chemicals, with sufficient evidences of carcinogenic potential 
in human (lARC, 1994). Physical agent such as ultra-violet rays (UV) and the 
ionizing radiation (X-rays, gamma-rays) are known to be hazardous in nearly all 
tissue or organs of human or experimental animals depending upon the radiation dose 
and exposure schedule (lARC, 1992). The scenario is becoming alarming with the 
application of nuclear technology in science, medicine and industries as well as in the 
expanding use of these radiations in diagnosis and therapy of the disease itself 
(Trichopoulus et al., 1996). 
Biological agent, such as retrovirus, bacteria and parasitic infections, the 
oncogenic virus such as papillomas viruses, feline- leukemia viruses and bovine-
leukosis virus are linked w i^th increased incidence of various types of Neoplasia. The 
Epstein-Barr virus has shovra to be implicated with the occurrence of Burkitt's 
lymphoma, Hodgkin and non- Hodgkin lymphoma and pharyngeal carcinoma 
(Cordova et al., 2003; Young and Murray, 2003). Certain bacteria like Helicobacter 
pyroli are also implicated in development of cervical, esophageal, head, neck and 
stomach cancer (Peto, 2001). 
Various factors that can play crucial role in establishment of cancer are host 
(internal) factors comprised of hormonal disturbance, immune functions and inherited 
predisposition of certain cancers. The genetic manipulation such as activation of 
cellular proto-oncogenes and alteration in tumor suppressor genes also results in 
aberrant proliferation of cells (Ames et al., 1995; Peto et al., 2001). Many cancer 
chemotherapeutic drugs, particularly Vinca alkaloids, Alkylating agent, 
immunosuppressive agent and certain cyclosporins are also reported to increase 
cancer risk. (Ames et al.^ 1995; Trichopoulus et al., 1996; Cheuveuet et al., 2QQ3). 
According to famous British pathologist, R.A. Wills (1960), tumor can be 
defined as, "An abnormal mass of tissue the growth of which is in excess and 
uncoordinated with the normal tissue and persists in the same excessive manner, even 
after the cessation of the stimuli that evoked the change. "The six major aUerations in 
cell physiology that collectively dictate malignant growths are (Hanahan and 
Weinberg, 2000) are: 
Self-sufficient in growth signals. 
Insensitivity to growth inhibitor signals. 
Evasion of apoptosis (programmed cell death). 
Limitless replicative potentials 
Sustained angiogenesis and adjoining tissue invasion. 
Metastasis. 
Each of these physiological changes acquired during tumor development 
represent the successfiil breaching of an anticancer defense mechanism. These six 
features are shared in common by most types of human and animal tumors. Aberrant 
DNA causes cancer. First, genetic mutations in critical genes can lead to tumors. In 
fact, in approximately one-half of human tumors, mutations exist in the tumor-
suppressor gene, p53. This is important because inactivation of the p53 gene allows 
for uncontrolled cell division. Another mechanism involved in carcinogenesis is DNA 
lesions. This refers to damaged bases or chromosome breaks that have a certain 
probability of producing a mutation upon cell division. The "effectiveness" of a 
particular lesion depends on the rate of excision by DNA repair enzymes, and on the 
probability that a mutation will occur when the cell divides. Cellular apoptosis or 
"programmed cell death" provides the body with a mechanism for removal of cells 
with damaged DNA. The effect that a particular insult has on the cell is dependent on 
the level of each of these defenses, which in turn are actually dependent on the past 
history of exposure. These defenses can also be disabled by lack of micronutrients 
such as antioxidants in the diet. 
At a molecular level, antioxidant deficiency is considered to be a risk factor 
for cancer, as it can lead to "unrepaired or misrepaired endogenous oxidative DNA 
damage" (Sahu and Washington, 1992) and membrane lipid peroxidation (LPO). Free 
radicals may mediate many events in carcinogenesis by producing damage to DNA, 
lipids, proteins, and carbohydrates. External sources of free radical include polycyclic 
aromatic hydrocarbons in food, polluted air, cigarette smoke, background radiation, 
and internal sources include oxidative transformations in prostaglandin synthesis, 
redox cycling of quinones, and oxidative phosphorylation (Block, 1992) 
Still another mechanism that may underlie for cancer is the excess free radical 
production in chronic infection and inflammation. Leukocytes and other phagocytic 
cells combat bacteria, parasites, and virus-infected cells by destroying them with 
nitrogen oxide and superoxide. Both of these compounds can lead to formation of 
peroxynitrite, hypochlorite, and hydrogen peroxide, all of which are mutagenic 
oxidizing agents. So, while these oxidants protect the body from immediate harm. 
they can cause oxidative damage to DNA, DNA mutation, and chronic cell death with 
compensatory cell division. All of these processes then contribute to cancer 
development. 
Cancer, one of the three major diseases in the U.S, is becoming more common 
in the Western world and also in many populations of developing countries. With 
modem medicine, some treatments have met with success, but they have been very 
expensive. It is becoming evident that the most cost-effective control of these 
diseases is through prevention. This is mainly achieved through the diet and other 
lifestyle changes (Argiles et al., 1998). In addition, cancer chemoprevention is a new 
field that has great potential to affect cancer incidence rates. Cancers can be 
prevented through lifestyle modifications; dietary measures have been estimated to 
have the potential to prevent about 30-40% of all cancers worldwide (WCRF/AICR, 
1997). Five of the ten leading causes of death for Americans are associated with diet: 
heart disease, some cancers, stroke, diabetes, and atherosclerosis (Glanz, 1997) The 
World Cancer Research Fund now recommends a plant-based diet rich in a variety of 
fruits, vegetables, and legumes along with reduction in the amount of processed 
starchy staple foods (WCRF/AICR, 1997). 
Strong epidemiological and experimental evidence inversely correlate plant-
based diets with the incidence of several types of cancers (WCRF/AICR, 1997). 
Specifically, the North American diet, associated with the highest incidence of 
cancer, correlated to high levels of saturated fat and low levels of plant-based foods. 
The lowest incidences of cancer were observed in populations with Mediterranean 
and Asian diets that were characterized as having a lower content of saturated fats and 
a higher rate of consumption of plant based foods such as legumes, vegetables and 
fhiits (Simopoulos, 2001). It has been suggested that several distinctive 
phytochemicals (vitamins, fibers and micronutrients) may be responsible for the 
protective effect of fruits and vegetables (Steinmetz and Potter, 1996; Flood et al., 
2002; Uzcudun et al., 2002; Littman et al., 2001). Conversely, another well-supported 
hypothesis is that high consumption of fruits and vegetables is protective against 
many cancers (Steinmetz and Potter, 1996). Block (1992), cites approximately 120 of 
130 studies conducted that show a statistically significant reduction of risk of cancers 
of the lung, larynx, esophagus, oral cavity, pancreas, stomach, rectum, cervix, colon, 
ovary, endometrium, breast, and bladder with increased antioxidant intake. More 
recently, scientists have been interested in investigating micronutrients, carotenoids 
and polyphenolic compounds, because of their potential as inhibitors of tumor 
growth. 
In in-vitro studies, phytochemicals have been found to inhibit leukemia cancer 
cell growth and induce apoptosis at different phases. Carotenoids have been shown to 
cause a GQ/GJ arrest in HL-60 myeloid leukemia cells (Palozza et al., 2002; Palozza et 
al., 2001; Amir et al., 1999). In addition, certain polyphenols have been responsible 
for a Gg/G, arrest in CEM leukemic T-cells (Yoshida et al., 1992) and a G2 arrest in 
HL-60 myeloid leukemic cells (Kang and Liang, 1997; Palozza et al.. 2002) 
demonstrated that carotenoids can induce apoptosis in HL-60 cells at the same 
concentration required for cell cycle arrest. For polyphenols, in general, there is a 
dose and time dependent induction of apoptosis in human leukemia cells (Csokay et 
al., 1997; Ferry-Dumazet et al., 2002). 
One important factor in the prevention on cancer is to assess the risk for 
cancer, which can be influenced by exposure to radiation, chemicals, hormones, 
infectious agents, chemicals, genetics and nutrition. It is expected that about one-
third of the number of cancer deaths will be associated with poor nutrition, physical 
inactivity and other lifestyle factors that can be changed (WCRF/AICR, 1997) 
ANATOMY OF CERVIX 
The cervix is situated in the lower part of the uterus and forms a narrow canal 
between the vagina and the uterine body cavity (Fig. 1). Cervical squamous 
epithelium consists of stratified epithelium (multiple layers typically 10-15 cell layers 
thick) and extends from the endocervical canal to the epithelium of the vagina (fig. 2). 
The layers of the epithelium are divided based on increasing maturation away from 
the basement membrane. Squamous (cubiodal) cells close to the basement membrane 
have a larger nuclear to cytoplasmic ratio than other squamous cells of the cervix; 
they are separated from the stroma by the basement membrane (fig.3). Cells undergo 
maturation as they move from the basal layer to the epithelial surface where they 
become more flattened and their cell volume increases. Tight junctions are dominant 
in the superficial layer, which reduces the extracellular space. Cell attachments in less 
mature cells consist of microfilaments that hold the cells together (Walker et al., 
2003). Cervical cancer arises in the basal cells of the cervical epithelium at a site 
called the transformation zone. This zone is sensitive since it forms a border between 
endocervical cylindrical epithelium and multilayered ectocervical squamous 
epithelium (Burghardt et al , 1983). 
There are two main types of cervical cancer called squamous cell carcinoma 
and adenocarcinoma. Squamous cell carcinoma derives from squamous cells that 
represent the majority of the cells in the lower cervix. This is the most common form 
of cervical cancer and constitutes 75% of all cases (Vizcaino et al., 1998). 
Adenocarcinoma which arise from cervical glandular cells are more rare and 
represent 10-15% while cervical cancer with other or without specified histology, 
make up the remaining 10-15%. (Euscher et al., 2001; Vizcaino et al., 1998). 
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Figure 2: Epithelium structure of the cervix. 
Figure 3: Histological image of cervical epithelium 
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Figure 4: Schematic illustration of the cervical epithelium. The fragile transformation 
zone forms a border between endocervical and ectocervical epithelium. 
Cervical carcinoma develops progressively through different stages from 
normal epithelium to cervical cancer in situ. The final step, invasive cervical 
carcinoma, is characterized by adhesion to and penetration of the basement membrane 
by the primary in situ tumor. After penetration, the cancer has potential to spread and 
form metastatic daughter tumors at other sites of the body. 
Histopathology of Cervical Cancer 
When HPV infection was detected in the epithelium, it may span a spectrum 
ranging from normal to condyloma planum (flat warts) or acuminatum (acuminate 
warts), to intraepithelial neoplasia and invasive cancer. Disease may occur at a wide 
variety of sites, including the conjunctiva, oral cavity, keratinized skin, and 
anogenital mucosa. HPV infection occurs in the basal cell layer of the epithelium, 
which constitutes the dividing cell population (Fig. 4) (Pfister, 1984; Howley et al.. 
1986). The importance of this observation is that the basal cells may then constitute a 
continuous reservoir of HPV DNA, and the viral genome is then partitioned to all 
daughter cells when the cells divide. HPV gene expression appears to be limited in 
the basal cell layer (Durst, 1992). However, as the cells begin to mature and rise 
through the epithelium, the viral DNA molecules continue to reproduce themselves in 
the absence of basal cell division, resulting in a higher HPV DNA copy number per 
cell. This process continues such that the highest DNA copy numbers per cell are 
found in the most mature cell layers, as indicated by in situ hybridization of HPV-
infected tissues (Durst, 1992, Fig. 2). As a result of increased viral copy number 
and/or alterations in keratinocyte factors that modulate HPV gene expression within 
mature keratinocytes, viral activity increases as the cells mature. 
Epidemiology 
In the United States, 85% of the annually reported communicable diseases are 
sexually transmitted infections (STIs), with the large majority consisting of those 
affecting men and women during their reproductive years. Eighty-six percent of these 
STIs occur among persons in the 15-29 year range. Human papillomavirus (HPV) 
was the most commonly reported STI in North America in the years 1998- 1999 and 
persistent cervical HPV infection was found to be a precursor for (as well as the most 
significant cause of) cervical cancer (Brackbill et al., 1999; Division of STD 
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Prevention 1997; Moscicki et al., 1989; Smith et al., 2003; Taira et al., 2004) In 
1999, Cervical cancer posed a significant public health concern, due to the fact that it 
was the second most prevalent cancer among women in the United States - after 
breast cancer - and the third most prevalent cancer among women worldwide, with a 
death rate of approximately 50%. One year later, it was found to be the second-
leading cause of cancer deaths in women worldwide, with HPV having been 
determined as the primary etiologic agent in more than 95% of cervical cancers 
(Parkin et al., 1999; Pisani et al., 1999; Stoler, 2000). In 2000, the estimated 
prevalence of HPV in the United States was 15%) to 20%) (Gerhardt et al., 2000). In 
2004, the American Cancer Society estimated that 10,520 women would be 
diagnosed with cervical cancer and 3,900 women would die from the disease (Centers 
for Disease Control [CDC], 2004a). Genital HPV infection is widespread, estimates 
show that as many as 75%o of women will become infected with one or more of the 
sexually-transmitted HPV types during her lifetime (Baseman and Koutsky, 2005) 
In addition, roughly 80 percent of individuals who acquire sexually 
transmitted HPV infections clear the virus rapidly without ever developing warts or 
other clinical symptoms (Dunne and Markowitz, 2006). Uterine cervical tumors kill 
several thousand people each year and represent a major disease burden in women 
worldwide (Schiffman and Castle, 2003). The presence of HPV in the vast majority 
of all cervical cancers worldwide offers the highest attribute reported for a specific 
cause of any of the major human cancers (Walboomers et al., 1999). Globally, 
approximately 500,000 new cases are identified yearly (World Health Organization. 
1999). 
Screening programmes 
The incidence of cervical cancer is generally low in developed countries with 
age-standardized rates less than 14.5 per 100,000 (Parkin et al., 2002). The main 
reason for the low incidence rates and decreased mortality of cervical cancer is the 
long-standing screening programmes initiated in the 1960's and 1970's. The birth of 
the screening for pre-stages of cervical cancer took place in year 1943 when Dc. 
Papanicolaou (Pap) invented a new histological staining procedure of vaginal smears. 
This new assay made it easier to detect abnormal cell differentiation in the cervix and 
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thereby also to detect lesions in the cervix and uterus (Papanicolaou, 1943; Frisch, 
1989). 
There are different Pap smear diagnoses, which reflect distinct types of 
morphological lesions observed during cancer development. The nomenclature 
describing the cytological status of a smear depends on the classification system used. 
There are four main systems for Pap smear diagnosis. The Papanicolaou system was 
presented in 1954 and is based on certainty that malignant cells are present in a 
vaginal smear (Kurman et al., 1994). This system was followed by a descriptive 
system in 1968 based on morphological criterias (Burghardt, 1973). The cervical 
intraepithelial neoplasia (CIN) system was introduced in 1978 and is applied by 
cytologists although derived from histology (Nguyen and Nordqvist, 1999). Finally, 
the Bethesda system was introduced in 1988 with the aim to increase the 
reproducibility within and between laboratories by reducing the number of categories. 
(Kurman et al., 1994; Nguyen and Nordqvist, 1999). 
The cytological screening for cervical cancer has generally been a success. 
Countries with widely accessible screening have experienced a 40-80% decrease in 
cervical cancer related mortality since the screening started. (Sigurdsson, 1999; 
Bergstrom et al., 1999). At present, women diagnosed with invasive cervical cancer 
in developed countries are mostly the ones who are screened irregularly or failed to 
attend screening (Geirsson, 1986; Janerich et al., 1995). 
The origin of cervical cancer (HPV) 
In 1843, Rigoni-Stem, an Italian physician in Rome, made the fist observation 
pointing to an infectious component in the etiology of human cancer (Hausen and De 
Villier, 1994b). He noted a difference between the calibrated nuns and prostitutes 
with respect to cervical cancer. The observation that prostitutes had much higher 
incidences of cervical cancer suggested that cervical cancer was sexually transmitted 
(Hausen and De Villier, 1994b). Recent epidemiological studies have confirmed this 
observation, and sexual activity (both male and female) represent the prime risk 
factor for cervical cancer (Bosch et al., 2002; Bosch and De Sanjose, 2002). It had 
been suggested that the Herpes Simplex type 2 (HSV 2) could be the causative agent, 
however Zur Hausen, were unable to demonstrate HSV DNA in the biopsies of 
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cervical cancer (Hausen, 1977). The establishment of cloning techniques allowed for 
the recognition of the first genital HPV type, HPV type 6 isolated from genital wart 
(Gissmann and Hausen, 1980). This was followed by the identification of another low 
risk HPV type, type 11 (Gissmann et al., 1982) as well as the high HPV type HPV 16 
(Durst et al., 1983) and HPV 18 (Boshart et al , 1984). 
During the past 20 years, it has been proved beyond reasonable doubt that 
certain types of sexually transmitted human papillomaviruses (HPVs) are necessary 
for the development of cervical cancer (Hausen, 1996, Bosch et al., 2002). HPV was 
found in close to every cervical cancer biopsy and the World Health Organization 
(WHO) has recognized cervical carcinoma as the first cancer to be 100% attributable 
to infection (Bosch et al., 2002; Walboomers et al., 1999). 
Morphology of Human Papillomavirus 
Papillomaviruses are common and widespread among higher vertebrates but 
exhibit strict species and tissue specificity. The viruses belong to the family of 
Papovaviridae (De Villiers, 1994, Hausen, 1994) and are characterized by a small, 
enveloped 72nm capsomere capsid and 55nm diameter with an icosahedral symmetry 
containing the viral genome (Klug and Finch, 1965, Klug, 1965). HPVs are relatively 
stable and because they have no envelope they can remain infectious for months in a 
moist environment. (Orth et al., 1978). 
Human papillomaviruses fall into two broad groups: low risk types, associated 
with cervical condylomas and CIN 1; and high risk types that are associated with 
cancer. Using data from 11 different case-control studies conducted in many areas of 
the world, the list of carcinogenic HPV types now includes HPV 16, 18, 31, 33, 35, 
45, 51, 52, 58 and 59 (Munoz, 2000). 
The clinical manifestations of these viruses are warts (papillomas and 
condylomas), which are small epithelial tumors. The majority of these are benign 
tumors that regress spontaneously in immunocompetent individuals. Modem 
classification of HPV types is based on DNA sequence differences within the coding 
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regions of the early proteins E6 and E7 and the late protein LI. Different genotypes 
have <90% homology in these regions. 
HPV genomes are maintained as episomes in the nucleus of normal infected 
cells. However, in cervical intraepithelial neoplasias (CINs) and even more frequently 
in cancers, HPV genomes are found integrated into the human chromosomes 
(Badaracco et al., 2002; Nagao et al., 2002; Peitsaro et al., 2002). During integration 
of the viral genome, a portion of the E2 gene is frequently deleted. 
HPV and Cancer development 
There are approximately 40 mucosal HPV types and these are frequently 
found in the anogenital tracts of men and women. Mucosal HPV types are often 
referred to as low-risk types and high-risk types, based on their carcinogenic 
potential. HPV 16 is the most prevalent among the oncogenic HPV types and is 
together with HPV 18 the type most commonly associated with invasive cervical 
cancers (Bosch et al., 1995; Clifford, 2005), these two high-risk types have been 
recognized by the WHO as carcinogenic agents for humans (Bosch et al., 1995, 
Bosch et al., 2002). HPV16 and HPV18 are together with HPV31 found in 
approximately 75% of all cases of progressive cervical cancer (Bosch et al., 1995). 
The main mechanisms behind the steps toward cancer involve the HPV E6 
and E7 proteins and are shown in (Figure 5). In the early 1970's it was recognized 
that E6 and E7 turn cells into mutator phenotypes by hindering anti-cancer pathways 
(Loeb et al., 1974). Since then it has been shown in tissue culture and animal models 
that E6 and E7 have ability to immortalize and transform epithelial cells (Hawley-
Nelson et al., 1989; Halbert et al., 1991; Munger et al., 2002). The means of 
damaging the human cell division regulation system and destroying the defense 
against tumor development by E6 and E7 are highly efficient. Transformed cells are 
prone to accumulation of mutations and chromosomal abnormalities, insensitive to 
anti-proliferative stimuli and brakes, which normally act to control cell division, and 
self sufficient in growth signals (Hanahan and Weinberg, 2000). Genomic instability 
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is a common characteristic in many progressed epithelial cancers (Lengauer et al., 
1997; Lingle et al., 2002; Pihan et al., 2003). 
The key action of the high-risk HPV E6 protein is inhibition of the tumor 
suppressor protein 53 (p53). In contrary to low-risk HPV, the high-risk E6 binds to 
p53 and promotes proteolytic degradation via the ubiquitin proteolysis pathway 
(Scheffner et al , 1990; Wemess et al., 1990; Huibregtse, et al., 1991; Scheffner et al., 
1993; Thomas et al., 1996; Hengstermann et al., 2001). The p53 protein works in the 
Gl-S interphase and activated in stressful conditions for the cell such as DNA 
damage, hypoxia and low levels of ribonucleoside triphosphate (Linke et al., 1996). 
Two major events are induced by p53, (1) cell growth arrest in the Gl phase followed 
by DNA repair and survival or, (2) apoptosis (Figure 5). The consequence of p53 
removal in the cell by the E6 protein is insensitivity to DNA damage and evasion of 
apoptosis. Mutations can accumulate when this DNA damage repair mechanism is 
negatively affected, an event similar to that in other human cancers. 
The HPV E7 is the major transforming protein with the same function in both 
low and high-risk types. The oncogenic potential of the E7 protein results from 
interference with the tumor suppressor (TS) retinoblastoma protein (pRb) (Dyson et 
al., 1989). Genes required for DNA replication and entry into S-phase is activated by 
the E2F-family of transcription factors. The pRb protein acts as a break in cells about 
to progress into S-phase by binding to E2Fs and E7 can bind and inactivate pRb 
(Dyson et al , 1989). Binding of pRb to the E7 oncoprotein results in release of E2Fs, 
which stimulate cell cycle S-phase entry and lead to cell replication (Munger et al . 
2001). Low-risk HPV E7 proteins have affinity to pRb but the E6 proteins are unable 
to interfere with p53 (Havre et al , 1995). It is currently unclear how low-risk HPV 
types overcome the p5 3-mediated apoptosis but the search for further cellular partners 
of E6 and E7 proteins is ongoing. 
Factors directly related to HPV 
In most women HPV infections lasts no more than a couple of years (Evander 
et al., 199S-, Mosdcki et al., 1998; Ho et al., 1998). Yet, some individuals are not able 
to clear infection and the virus persists many years in the cervical epithelial basal 
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layer. Prolonged duration of a HPV infection, also called persistence, is strongly 
associated with risk of developing cervical cancer. The persistence of an HPV 
infection, particularly high-risk types, is associated with higher risk for abnormal Pap 
smear (Ho et al., 1998) malignant cervical epithelial neoplasia (Ho et al., 1995; 
Schlecht et al., 2001), and invasive carcinoma (Wallin et al., 1999). The relative risk 
(RR) of incident squamous intraepithelial lesion (SIL) is about ten times higher for 
persistent infections with oncogenic HPV type relative to non-oncogenic. low-risk 
HPV types. Especially for HPV 16 and HPV 18 there is a strong relationship between 
persistence and SIL (Schlecht et al., 2001). Persistence is now a widely established 
risk marker for the disease but the number of years required for development of 
cancer is not known exactly. Persistence of oncogenic HPV is also associated with 
high viral load (Beskow et al., 2002; Dalstein et al., 2003). 
Factors indirectly related to HPV 
HPV infections are transmitted through sexual contact and the probability of 
exposure to HPV is therefore directly related to an individual's sexual activity. Many 
parameters regarding the sexual behavior have been linked to cervical cancer. 
However, most of them are just indirect measures of HPV exposure and are therefore 
not direct risk factors for cervical cancer. For instance, the risk of HPV infection 
increases with earlier age at sexual debut, number of sexual partners, frequency of 
intercourse and anal sex (Koutsky et al., 1992, Schiffman et al., 1993, Andersson-
EUstrom et al., 1996). In other words, there must be some further risk factors or 
cofactors that take part in the process of cervical carcinogenesis. 
Cigarette smoking 
Although studies show no direct association between smoking and cervical 
neoplasia (Zaninetti et al., 1986) but there are some evidence that shows cigarette 
smoking increases the risk (Becker et al., 1994; Reeves et al., 1987; Ylitalo, 1999). 
Some observations have also suggested that there may be an interaction between HPV 
and smoking in the causation of cervical neoplasia (Herrero, 1989; Hildesheim et al., 
2001). However, reports are available that smoking is significantly associated with 
cervical carcinoma (52% of cases vs. 27% controls) but is not associated with HPV 
infection (Reeves et al., 1987). 
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Figure 5: The mechanisms of high-risk HPV E6 and E7 proteins. The proteins 
interact primarily with p53 and pRb, which leads to transformation of the cell. 
Illustration by Dr. M. Moberg. 
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The confusion about the possible relation between smoking and cervical 
neoplasia and between smoking and HPV infection indicates that smoking might be a 
weak factor to impact the development of cervical neoplasia and the infection of 
HPV. It is difficult to control the investigative settings of epidemiological studies to 
get consistent results. Seemingly, cigarette smoking at the most is a minor cofactor of 
some specific types of HPV in certain populations. 
Hormonal contraception 
It has been shown that long-term use of hormonal contraceptives tends to 
increase the risk of cervical neoplasia (Ylitalo et al., 1999; Hildesheim et al., 2001; 
Reeves, 1985; Vessey et al., 1989) or increase the HPV infection (Chang, 1989). By 
contrast, women using barrier contraceptives and spermicidal foams or jellies seem to 
be at lower risk for this neoplasm (Celentano et al., 1987). However, hormonal 
contraceptive reduces the risk of cervical neoplasm (Pike et al., 2000). Like smoking, 
hormonal contraception might be another weak cofactor of HPV infection in the 
development of cervical neoplasia. 
Inheritance 
Genetic factors are an attractive field although so far no specific oncogenes or 
tumor suppressor genes have been found. Significant family clustering of Swedish 
cases among biological, but not adoptive, relatives of patients with cervical tumors, 
which provided an epidemiological evidence of a genetic predisposition to cervical 
carcinoma has been reported (Magnusson et al., 1999). Several other articles with 
similar conclusion were also published (Magnusson, 2000; Maciag et al., 2000; 
Hemminki et al., 1999; Hemminki et al., 2001). They explained that genetic 
susceptibility to HPV infection appears to be important in determining the individual 
risk to develop this virally induced cancer. 
OTHER RISK FACTOR 
Lack of vitamins and carotenoids (Slattery et al., 1990; Potischman and 
Brinton, 1996) has also been linked to CINII and invasive cervical cancer. The age at 
viral exposure is known to influences the risk of several other cancer forms, such as 
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Hepatitis B induced liver cancer (Coursaget et al., 1987) and Epstein stain virus 
induced Burkett's lymphoma (Magrath et al., 1992). Whether the association seen 
between age of first intercourse and risk of cervical cancer is an artifact of mere risk 
of HPV exposure or if it increases the risk between HPV-exposed remains to be 
shown. Other infectious agent such as- Chlamydia trochomatis and herpes simplex 
virus (HSV) 2 are suggested to have co factorial role in some case of cervical cancer 
but the association are weak and inconsistently found (Lehtinen et al , 2002; Smith et 
al., 2002). Proposed explanation includes enhanced access to basal membrane and 
increased proliferation due to inflammation. 
It has been pointed out that the association between HPV and cervical cancer 
is higher than the association between smoking and lung cancer and only the 
association between the chronic carrier state of hepatitis B infection and liver cancer 
is stronger (Franco, 1995). 
Signs and Symptoms 
Symptoms for women with HPV in the absence of cancer range from no pain 
or symptoms to pain and irritation due to inflammation and the development of warts. 
Visible manifestations of HPV infections are anogenital warts located on the vulva, 
vagina and cervix (Keller et al., 1995). In detected cases, emotional distress often 
occurs (Kreitler et al., 1996). Pre-cancerous changes of the cervix are typically found 
to be relatively asymptomatic. Symptoms usually occur if abnormal cervical cells 
metastasize into surrounding cellular areas, causing abnormal vaginal bleeding and/or 
discharge and painfiil intercourse. In advanced cancerous stages, women report pelvic 
pain, heavy vaginal bleeding and edema (Women's Cancer Network [WCN], 1999). 
Current treatments for HPV-induced cancers of the uterine cervix 
Treatment options for HPV positive uterine cervical tumors vary with the 
stage of disease at diagnosis, the health of the patient, and desire for bearing children, 
but in all cases involves surgical removal of the malignant tumor (Moore, 2006) as 
early stages tumors are curable by surgical intervention alone. Procedures such as the 
Loop Electrosurgical Excision Procedure (LEEP) and Trachelectomy are conservative 
treatments that allow a patient to bear children in the fiiture (Schlaerth and Abu-
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Rustum, 2006). In more advanced stages of cervical cancer, hysterectomy is the 
treatment of protocol, and in the most advanced stages, radical surgery called pelvic 
exenteration, which includes removal of all pelvic organs (bladder, rectum, cervix, 
and vagina), is performed (Moore, 2006). 
In more advanced cases as well as in cases of recurrent cervical cancers may 
require the use of radiation and/or chemotherapy in addition to surgical treatment. A 
variety of chemotherapeutic drugs can be used to treat cervical cancer. The standard 
first line treatment for invasive cervical cancer is usually cisplatin (Platinol) and 5-
fluorouracil (5-FU, Adrucil, Efudex) used in combination and in addition to radiation. 
Recurrent and late stage cervical cancers are often treated with a combination of 
platinum, bleomycin, methotrexate, and 5-FU (DuPont and Monk, 2006). 
Chemotherapy is administered intravenously, through injection, or in pill form. Side 
effects often accompany treatment and may be severe, they can include nausea, 
vomiting, diarrhea, and leukopenia (low white blood cell count). Most of these side 
effects are a result of drug toxicity to healthy tissues such as skin, hair follicles, and 
epithelial cells that line the digestive tract (Stewart and Viswanathan, 2006). Patient 
tumors can develop resistance to these therapies as well (Muggia, 2004). Hence, there 
is the need to develop alternate, safer, less toxic, and more specific therapies for 
UCC. 
CHEMOPREVENTION 
Some of the most successftil currently used anticancer compounds are extract 
from plants or other natural products. These include the breakthrough class of drugs 
known as catechins that come from the tea plant {Camellia sinensis), and the vinca 
alkaloids (Vincristine, Vinblastine, Vinorelbine), which are derivatives from the 
periwinkle plant {Catharanthus roseus). Other examples of natural products include 
the antitumor antibiotics such as anthracyclines, dactinomycin, bleomycin, 
adriamycin, and mithramycin, which are all compounds derived from fungi. These 
compounds affect the growth of all rapidly dividing cancerous cells. 
Millions of research dollars each year go to the discovery of new natural 
products with limited side effects that may be used as effective antitumor agents. 
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Some compounds that are currently being investigated are components of dietary 
plants (Wilson and Danishefsky, 2006; Tan et al., 2006). Examples of such 
compounds are resveratrol, indole-3-carbinol, quercetin and other catechin 
compounds, azaphilones, and flavonoids. Many of these potential drugs are 
antioxidants and fall into a class of chemical compounds called polyphenols. It is 
believe that the chemopreventive activity of catechin (green tea) is due to the 
antioxidative and possible anti-proliferative properties of catechins (Bokuchava and 
Skobeleva, 1980). One of the principal goals of cancer chemotherapeutic or 
chemopreventive agents is the elimination of damaged or malignant cells through cell 
cycle inhibition or induction of programmed cell death (apoptosis), leaving normal 
cells unaffected (Srivastava and Gupta 2006). 
The nutritional etiology of cervical neoplasia includes low dietary intake of 
vitamin C, carotenoids, vitamin E, and folate. For example, Nagata et al. (Nagata et 
al., 1999) reported a case-control study that suggested the role of plasma carotene in 
preventing cervical cancer in Japan. Many epidemiological and analytical studies 
have been conducted to investigate the relationship between antioxidant nutrients and 
cervical cancer (Mackerras et al., 1999; Sharmon et al., 2002; Wideroff et al, 1998; 
Head, 1998). Today researchers are engaged all around the world to investigate 
beneficial effect of Green tea polyphenol especially EGCG green tea by exploring it 
as an anticancer agent. 
Epigallocatechin Gallate (EGCG) 
Apart from water, tea and coffee are the most widely consumed beverages 
worldwide (Islam et al., 2000; Roy et al., 2009; Siddiqui et al., 2009). Both contain 
chemical substances having antioxidant properties that may impact on human health. 
These substances include caffeine and polyphenols. Tea beverage is made from 
processed leaves of the plant Camellia sinensis a evergreen herb of Theaceae family 
(J). Based on the Ch'a Ching (Classic of Tea), tea was discovered in 2723BC by 
Emperor Shen Nung of China and was used exclusively for medicinal purposes 
before the Tang Dynasty (618 - 906AD). Tea was consumed as soup with onions, 
ginger or orange peel and salt. In the Song Dynasty (906- 1279AD), traditional tea 
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leaves were powdered to produce a bright green and low astringency frothy drink, 
which is known as Mattcha in Japan today. It was not until the Ming Dynasty (1369 -
1644AD) that tea leaves were brewed in hot water. This coincided with the arrival of 
westerners in China. Today, various tea-brewing techniques are used across cultures 
(Harbov^ and Balentine, 1997). 
In general, there are three types of manufactured tea: black tea, oolong tea and 
green tea. The type of tea manufactured depends on the degree of oxidation of leaves. 
Oxidation is an exogenous process: i.e. the natural browning of leaves catalysed by 
enzymes within the tea leaf (Harbowy and Balentine, 1997; Urmo and Takeo, 1995; 
Unnoetal., 1996). 
Green tea extracts have been used in traditional Chinese medicine for 
centuries to treat and prevent chronic disease (Liao, 2001) but conventional medicine 
practitioners have only recently begun to explore the health-promoting benefits of 
green tea derivatives (Cabrera et al., 2006). In present study, focus is on the potential 
antioxidative effects of (-)-epigallocatechin-3-gallate (EGCG), which is the most 
abundant polyphenolic compound found in green tea (making up more than 40% of 
the total polyphenolic mixture (Jung et al., 2001). Because EGCG acts against cancer 
through a variety of mechanisms, its potential for use in human cancer prevention and 
treatment seems very promising. The growing number of in vivo and in vitro research 
studies on this topic reflects this potential. However, to date, relatively few large-
scale epidemiological studies in western populations and randomized, controlled 
intervention trials have been conducted. 
EGCG is colorless, astringent, water-soluble, and readily oxidizable (Graham, 
1992). Its catechol structure also makes EGCG a strong chelator of metal ions (Guo et 
al., 1996). EGCG can bind the transition metal ions, prevent formation of hydroxyl 
radicals, and thus inhibit exogenous ROS-potentiated tumor invasion (Zhang et al.. 
2000). The oxygen scavenging effects of EGCG are superior to those of ascorbic acid 
(vitamin C) and tocopherol (vitamin E) with respect to some active oxygen radicals 
(Zhao etal., 1989). 
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Figure 6: Structure of Epigallocatechin-3-gallate 
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Thus, EGCG could inhibit tumor cell invasion by scavenging oxygen radicals. 
It has high affinity for the lipid bilayers of the cell membrane, and can easily enter the 
nuclei of cancer cells (Okabe et al., 1997). EGCG, because of its polyphenolic 
structure, have been shown to exhibit antioxidant properties, free radical scavenging 
and chelation abilities (Castillo et al., 2002; Kimura et al., 2002; Young et al., 2002; 
Yang et al., 2002, Zhang et al., 2000). 
The vicinal dihydrogen or trihydrogen structure contributes to these 
antioxidant activities. These compounds have also been reported to exert anti-
inflammatory actions and modulate immune functions. They exert a cholesterol-
lowering effect by enhancing reverse cholesterol transport and bile acid excretion, 
and decreasing the intestinal absorption of dietary cholesterol (Abe et al., 2000; 
Chugh et al., 2003; Maron et al., 2003). Anti-carcinogenic properties of EGCG 
associated with cytotoxicity to cancer cells have also been suggested (Ahmad et al., 
2000; Krul et al., 2001; Kubo et al., 2002). In addition, various epidemiological 
studies have observed an inverse relationship between flavonoid consumption and 
coronary heart disease and stroke (Beretz et al., 1982; Hakim et al., 2003; Kris-
Etherton et al., 2002a; Kris-Etherton 2002b). 
One of the most frequently studied mechanisms of EGCG is its role as an 
antioxidant. Cancer development may be associated with oxidative damage to DNA, 
lipids, and proteins. Oxidative damage to cells may be caused by a number of factors, 
including UV light, carcinogens, and free radicals (Rietveld and Wiseman, 2003). 
Oxidative damage to DNA is an important source of gene mutations that modify gene 
expression and cellular regulation (Rietveld and Wiseman, 2003). Oxidative damage 
in cells can be assessed indirectly by measuring the byproducts of oxidative damage, 
such as oxidized derivatives of phosphatidylcholine in lipid damage and 
8-hydroxyguanosine in DNA damage (Frei and Higdon, 2003; Rietveld and Wiseman 
2003). EGCG has been found to reduce significantly the plasma levels of biomarkers 
for oxidative damage to both lipids and DNA (Rietveld and Wiseman 2003). The 
effect of EGCG on oxidative protein damage also has been studied, and results are 
mixed. In rats, EGCG was found to suppress oxidative modification of muscle 
proteins, however controlled studies in humans showed no effect of EGCG on 
biomarkers for oxidative protein damage (Frei and Higdon, 2003). Furthermore, 
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antioxidant molecules including EGCG, can alter the redox potential of the cell, 
thereby activating p53 and promoting apoptosis (Chung et al., 2003). In one in vitro 
study, cervical cancer cells exposed to 35 i^M of EGCG were arrested at the Gl phase 
of the cell cycle, whereas those exposed to 100 j^ M of EGCG underwent apoptosis, 
suggesting that low concentrations of EGCG promote cell cycle arrest whereas high 
concentrations trigger apoptosis (Ahn et al., 2003). 
Mechanism of EGCG against tumor progression and development 
Urokinase, a hydrolase implicated in tumor cell invasion (Huang et al., 2000) 
facilitates degradation of the basement membrane and extracellular matrix. Urokinase 
is over expressed in breast, ovarian, and prostate malignancies and has clearly been 
demonstrated to play an essential role in metastasis formation (Gohji et al., 1997). 
Inhibition of urokinase-type plasminogen activator (uPA) activity can reduce tumor 
size or even cause complete remission of tumours in mice (Jankun et al., 1997a). 
EGCG directly impairs the activity of urokinase, interfering with its enzymatic 
activity and thus its role in the degradation of extracellular matrix (Jankun et al., 
1997b). 
EGCG-mediated inhibition of matrix metalloproteinase 
MMP-2 and MMP-9, the MMP's most frequently over-expressed in cancer and 
in activated endothelial cells, are instrumental in degrading the basement membrane 
and facilitating cell invasion (Liotta et al., 1980). In experimental systems, cellular 
invasion is reduced by the presence of endogenous tissue inhibitors of 
metalloproteinases (TIMPs) and synthetic inhibitors of MMPs (Li et al., 2001). Some 
synthetic MMP inhibitors are currently being used in clinical trials for cancer therapy. 
Unfortimately, initial results have been disappointing due to undesirable side-effects, 
particularly musculoskeletal pain. Reports show that the concentration of EGCG that 
effectively inhibits MMP- 2 and MMP-9 in vitro is orders of magnitude lower than 
that reported for inhibition of urokinase activity (1/500) (Gabrisa et al. 2001). 
Because EGCG can form complexes with proteins and metal ions, the inhibition of 
MMP activities by EGCG may be partially related to its ability to chelate zinc, which 
is essential for MMP enzymatic activity (Maeda-Yamamoto et al, 1999). 
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Objectives of the present study 
It's well known that not much study has been carried out on the role of 
EGCG- a natural antioxidant on cervical cancer monocytes in comparison to its 
respective cell lines i.e. HeLa cell lines. Thus, in the present study, the main 
objectives were to probe the programmed cell death induced by EGCG in cervical 
cancer monocytes and its biopsies and in turn, compare the efficacy of EGCG in 
cervical cancer monocytes with those in HeLa cell lines. The study involves 
immimological investigations, caspase-3, 8 and 9 assays, PARP-cleavage, FITC-
Annexin assay, growth kinetics, cell cycle and cell viability assays, evaluation of 
protein expressions of Bcl-2 and TNF-alpha, IL-1 and IL-6 assays, etc. It is hoped 
that the results of the present study may probably help in the better understanding of 
the management of patients with cervical cancers. 
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Materials: 
N-acetyl-cysteine CNAC), H2O2, Agarose, Bovine serum albumin, Coomassie Brilliant 
Blue G-250 and R-250, p-nitrophenyl phosphate, anti-human IgG alkaline phosphatase 
conjugate, Tween-20, TEMED (N,N,N'N'-Tetramethylethylinediamine), dithiothreiotol 
(DTT), Phenylmethylsulphonyl fluoride (PMSF), Sodium azide, Ethidium bromide, 
Cumene hydroperoxide were from Sigma Chemical Company, U.S.A. Caspase 3 and 
PARP were from Bioscience, USA. Caspase-9 was from Bioivision, USA. BcJ-2, rabbit 
anti human antibody, was from Santa Cruz, USA. Fetal calf serum, antibacterial and anti 
fungal antibiotics were from Intergen, NY, U. S. A. Chloroform and Isoamyl alcohol 
were from Qualigens, India. Reduced glutathione. Glutathione reductase and reduced |3-
nicotinamide adenine dinucleotide phosphate were from HiMedia Chemical Company, 
India. 
EGCG a Green tea polyphenol was obtained from Sigma Chemical Company, USA. 
RPMI-1640 medium were from HiMedia, India. MTT cell viability assay kit was from R 
& D Systems; U.S.A. I2-wells tissue culture plates were obtained from Techno Plastic 
Products (TPP), Switzerland. Polystyrene microtitre flat bottom ELISA plates having 96 
wells (7 mm diameter) were from NUNC, Denmark. All other chemicals were of the 
highest analytical grade available. 
Study subjects: 
Venous blood was obtained from healthy nonsmoking adult volunteers with no history of 
any disease. Also, blood from patients with cervical cancer was obtained from the 
patients admitted to J. N. Medical College Hospital of A.M.U., Aligarh. The diagnosis of 
cervical cancer was based on Pap smear and later confirmed by pathological examination 
of biopsies. Serum was separated and stored at -20°C until required. 
Methods 
1. Determination of protein concentration: 
Protein was estimated by the methods ofLowry et al. (195 J) and Bradford (J 976). 
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This method is based on strong binding of the dye Coomassie Brilliant Blue G-250, in 
acidic medium, to protein hydrophobically, and at positively charged groups (Bradford, 
1976). In the environment of these positively charged groups, protonation is suppressed 
and a blue color develops (>.max-595 nm). 
Preparation of dye: 
100 mg of Coomassie Brilliant Blue G-250 was dissolved in 50 ml of 95% ethanol and 
100 ml of 85% (v/v) orthophosphoric acid was added. The resulting solution was diluted 
to a final volume of 1.0 litre and filtered through Whatman No. 1 filter paper to remove 
undissolved particles. 
Procedure: 
To 1.0 ml of solution containing 10-100 ug protein was added 5.0 ml of dye solution. The 
contents were mixed thoroughly by vortexing. The absorbance was read at 595 nm after 5 
minutes against a reagent blank. 
Polyacrylamide gel electrophoresis of proteins: 
Polyacrylamide gel electrophoresis was performed under denaturing conditions as 
described by Laemmli (1970). 
Reagents: 
(i) Acryiamide-bisacrylamide (30:0.8) 
A stock solution of 30% acrylamide containing 0.8% bisacrylamide was prepared by 
dissolving 30 gm of acrylamide and 0.8 gm of bisacrylamide in a total volume of 100 ml. 
The solution was stored at 4°C in an amber coloured bottle. 
(ii) Resolving gel buffer 
A stock solution was prepared by dissolving 36.3 gm Tris base in 48 ml of IN HCI. The 
contents were mixed, pH adjusted to 8.8 and the final volume brought to 100 ml with 
distilled water. 
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(A) Protein estimation by the Lowry (Folin-Ciocalteau) method: 
Protein estimation by this method involves complexing of the protein's peptide bonds 
with Cu2+ under alkaline conditions (Lowry et al., 1951). The resultant Cu+ appears to 
catalyze the oxidation of tyrosine and tryptophan residues by reducing 
phosphomolybdotungstate anions in the Folin's reagent (a mixture of sodium tungstate, 
molybdate and phosphate), added subsequently. This reaction develops a blue color due 
to the formation of heteropolymolybdenum blue, which can be quantified by its 
absorbance at 660 nm. 
Reagents: 
(i) Folin-Ciocalteau reagent 
The reagent was diluted 1:4 with distilled water before use. 
(ii) Alkaline copper reagent 
The components of alkaline copper reagent were prepared as follows: 
(a) 2% sodium carbonate in 100 mM NaOH. 
(b) 0.5% copper sulphate in 1% sodium potassium tartarate. 
The working reagent was prepared fresh before use by mixing the two components in the 
ratio 50:1, respectively. 
Procedure 
To 1.0 ml of protein sample was added 5.0 ml of freshly prepared alkaline copper 
reagent. After thorough mixing, the reaction mixture was allowed to stand at room 
temperature for 10 minutes, followed by the addition of 1.0 ml of 1:4 times diluted Folin-
Ciocalteau reagent. The contents were mixed immediately. The reaction was allowed to 
proceed for 30 minutes at room temperature and each tube was subsequently monitored at 
660 nm. The protein content of the unknown sample was determined by using bovine 
serum albumin to construct a standard calibration curve. 
(B) Protein estimation by the Bradford method: 
27 
(iii) Stacking gel buffer 
6.05 gm Tris was dissolved in 40 ml distilled water, pH adjusted to 6.8 with 1 N HCl 
and the final volume adjusted to 100 ml with distilled water. 
(iv) Electrode buffer 
3.03 gm Tris, 14.4 gm glycine and 1.0 gm SDS were dissolved in distilled water, pH 
adjusted to 8.3 and the final volume made up to 1.0 litre with distilled water. 
(v) Sample buffer 
a. 6.0 gm of Tris was dissolved in 80 ml distilled water and pH adjusted to 6.8 
with phosphoric acid. The final volume was brought to 100 ml with distilled 
water. 
b. 1.0 mg of bromophenol blue and 12.5 ml of glycerol were added to 12.5 ml of the 
above solution. B-mercaptoethanol was added just before use. 
Recipe for 12.5% Native Gel 
Reagents 
Acrylamide-bisacrylamide (30:0.8) 
Resolving gel buffer 
10% SDS 
10% Ammonium persulphate (APS) 
TEMED 
12.5% 
4.1 ml 
2.5 ml 
150^1 
50 ^l 
12 ^l 
The final volume was raised to 10 ml with distilled water. 
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Procedure: 
The glass plates (18 cm x 16 cm) were soaked in chromic acid and thoroughly washed 
with tap water followed by a final rinse with distilled water and ethanol. The plates were 
dried and sealed with 1% agarose using 1.5 mm thick spacers. The reagents were mixed 
and poured between the glass plates, a well-forming comb was inserted immediately and 
the gel was left to polymerize at room temperature. After ensuring complete 
polymerization, the protein samples (20-100 ^g) in one-fourth volume of sample buffer 
were electrophoresed at 80 volts at room temperature. The gels were stained using 0.25% 
Coomassie Brilliant Blue R-250 or with silver stain reagent. 
Preparation of whole cell lysate: 
Principle: 
Keratins are insoluble proteins. Therefore they are obtained by solubilizing with 
detergents like SDS or urea. Therefore, a SDS-lysis buffer is used which has EDTA and 
EGTA, which chelates the calcium ions, and SDS denatures the proteins. The cell 
suspension was subsequently sonicated, to cause cell disruption by shear forces by high-
pressure sound waves, shears the DNA that is then pelleted down by centrifugation. 
Therefore the supernatant will have only the proteins of the cells. 
Materials: 
IxPBS 
SDS lysis buffer 
20mM Tris pH 7.2 
5mM EDTA pH 8 
5mM EGTA pH 8 
0.4% SDS 
Procedure: 
1. The adherent cells in the dish are washed twice with 1X PBS. 
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2. 300 ^L of SDS lysis buffer was added to the cells. 
3. The adherent cells are scraped off with a rubber policeman. 
4. The cell suspension was transferred into an eppendorf tube and incubated on ice 
for 45min. 
5. The cell suspension then centrifuged at 10,000 rpm for 10 min at 4°C. 
6. The supernatant was taken in fresh tubes and was stored. 
Estimation of Proteins by Peterson Method 
Principle: 
Peterson method is a modified Lowry's method. The principle behind this method is that 
the, peptide nitrogen reacts with cupric ions under alkaline conditions and there is 
subsequent reduction of the Folin-Ciocalteau phosphomolybdic- phosphotungtic acid to 
heteromolybdenum blue by the copper catalysed oxidation of aromatic acids. Tartrate 
enhances the reduction of the Folin's reagent by cuprous ions. 
Reagents: 
• Bovine Serum Albumin (BSA) (Img/ml) stock solution. 
• Folin-ciocalteau reagent (1:5 ratio) 
CTC solution: 
o CTC reagent : (20%Na-bicarbonate+0.2%copper sulphate+0.4% sodium-
potassium tartrate) 
o 0.8N NaOH 
o 10%SDS 
o Distilled water 
(Each should be in ratio of 1:1:1:1) 
Procedure: 
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1. Gradients of the standard BSA between 5^L and 25nL were taken and 1 O^L of 
samples were taken. 
2. The volume of the samples and of the standard BSA was made up to 1ml with 
distilled water. 
3. To all the tubes, 1ml of CTC solution was added. 
4. The mixture was mixed well and was incubated for 10 min at room temperature. 
5. 0.5mL of Folin - ciocalteau reagent was added to the mixture. 
6. The mixture was mixed well and incubated for 30 min at room temperature in 
dark. 
7. The absorbance was measured at 750nm. 
Sodium dodecyl sulphate-polyacrylamide gel electrophoresis (SDS-PAGE) 
Principle: 
SDS-Page is the most widely used method for analyzing protein mixtures qualitatively. 
SDS is an anionic detergent. The mercaptoethanol in the sample buffer reduces any 
disulphide bridges present that are holding together the protein tertiary structure, and the 
SDS strongly binds to, and denatures, the protein. The original native charge is therefore 
lost completely. The sample buffer also contains an ionisable tracking dye, bromophenol 
blue (BPB), that allows the electrophoretic run to be monitored, and sucrose or glycerol, 
which gives the sample solution density thus allowing the sample to settle easily through 
the buffer to the bottom when injected into the loading well. 
A stacking gel is poured on top of the resolving gel. The purpose of the stacking gel is to 
concentrate the protein sample into a sharp band before it enters the main separating gel. 
Once the proteins reach the separating gel as a result of the small pore size, the negatively 
charged protein-SDS complexes now continue to move towards the anode, and, because 
they have the same charge per unit length, they travel into the separating gel under the 
applied electric field with the same mobility. However, as they pass through the 
separating gel the protein separate, owing to the molecular sieving properties of the gel. 
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The bromophenol blue dye is totally unretarded as it is a small molecule and therefore 
indicates the electrophoresis front. 
After the electrophoretic run, the gel is stained with the Coomassie brilliant blue (CBB) 
staining solution, where the Coomassie dye binds non-specifically to the aromatic amino 
acids of the proteins. The acetic acid and methanol mixture fixes the proteins onto the gel 
so that they will not get washed whilst they are being stained. The excess stain is then 
eluted using the same acetic acid - methanol - water mixture in the absence of the dye. 
Reagents: 
30% Acryl amide- Bisacrylamide solution 
[Acryl amide - 29.2g 
Bis-acrylamide - 0.8g] 
l.SMTris buffer-pH 8.8 
IMTris buffer-pH 6.8 
TEMED 
10% Ammonium persulphate(APS) 
10%SDS 
Sample Buffer: 
0.5M Tris pH 6.8 1.25mL 
Distilled water 3.55mL 
Glycerol 2.5mL 
10%SDS 2mL 
Bromophenol blue(0.5% W/W) 0.2mL 
5X Tank buffer: 
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Tris base (0.1 M) 1.5 Ig 
Glycine (1.25M) 9.4g 
10%SDS 5mL 
The mixture was then made up to lOOmL with distilled water. 
Staining Buffer: 
0.25% (w/v) CBB in methanol: water: acetic acid (45: 45:10 by volume) mixture. 
. Molecular weight marker (Page ruler Unstained Protein Ladder - Fermentas-Cat 
No: SM0661) 
» Resolving gel mix (for 10% gel): 
30% Acyrlamide solution 3.33 mL 
1.5 M tris pH8.8 0-9 mL 
Distilled water 3.6 mL 
TEMED 25 ^L 
10% APS 40 nL 
10%SDS 100 ^L 
• Stacking gel mix: 
30% Acyrlamide solution 750 |iL 
lMtrispH6.8 1.25 mL 
Distilled water 3mL 
TEMED 12.5 ^ iL 
10% APS 20 i^L 
10%SDS 50 ^L 
Procedure: 
1. The apparatus was fixed and checked for leakage 
2. 5 mL of the resolving gel mix was poured which is followed by stacking gel 
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3. The comb was placed immediately 
4. When gel has polymerized, the comb was removed and the apparatus was set in 
the electrophoresis apparatus. 
5. The tank was filled with the electrode buffer and the molecular weight marker 
(lO^L) and the samples were loaded. 
6. Electrophoresis was carried out at 200 V till the dye front reaches the end of the 
gel. 
7. The gel was then removed and stained using Coomassie brilliant blue staining 
solution for 2 hours in a rocker. 
8. The gel was then destained using the destaining solution. 
Western Blotting 
Principle: 
Western blotting is an analytical method used to detect the specific protein present in the 
cell lysate. The proteins are resolved on a SDS-Polyacrylamide gel and are then 
electrotransferred on to the Polyvinylidine Fluoride (PVDF) membrane. PVDF 
membrane has non-specific affinity for amino-acids. Protein binding is based on the 
hydrophobic and charged interactions between the membrane and the proteins. After 
electroblotting, staining the membrane with the Ponceau staining solution checks the 
efficiency of transfer. 
The membrane is then probed with the mouse anti-GFP antibody (primary antibody), 
after having it blocked with Bovine Serum Albumin (BSA), which binds specifically to 
the Green Fluorescent Proteins (if present on the membrane). The membrane is then 
probed with a secondary antibody (anti-mouse), which binds specifically to an epitope of 
the primary antibody. The secondary antibody is conjugated with the Horse-Radish 
Peroxidase (HRP) enzyme. Subsequently, on the addition of acridinium based ECL plus 
substrate, the enzyme catalyses the conversion of the chromogenic substrate into a 
product (acridinium esters), which produces luminescent signals. These signals are 
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captured in an X-ray film, which is then developed to visualize the signals. Bands wil 
appear as dark regions on the developed film. 
Reagents: 
Transfer buffer 
9.1 g 
43.2g 
600mL 
3mL 
50mL 
50mL 
D Tris base (0.02M) 
0 Glycine (0.2M) 
D Methanol 
o 10%SDS 
The volume is made up to 3L with distilled water. 
• Ponceau staining solution 
o 0.1% Ponceau S in 1% acetic acid 
• lOX Tris buffered saline (TBS): 
o IMTrispHS 
o 5M sodium chloride 
The volume was made upto 500 mL with distilled water. 
• TBST 
o 0.1%Tween20inlXTBS. 
• Blocking solufion 
o 3%BSAinlXTBS 
• Antibody dilutions 
The antibodies are diluted with appropriate amounts of 0.5% BSA in IX TBS. 
• ECL plus Western Blot Detection System (Amersham, Cat. No: RPN2132). 
Procedure: 
1. The protein samples were resolved using 10% SDS-PAGE and were 
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transferred to the gel transfer cassette. 
2. PVDF membrane was pre-activated with 100% methanol. 
3. The membrane was then washed with water and subsequently saturated with 
transfer buffer. 
4. The membrane was placed on top of the gel in such a way that there is no air-
bubble in between the gel and the membrane. 
5. The cassette was fixed and was run at 100 V for 1 hour. 
6. The membrane was washed with distilled water. 
7. The membrane was then removed and stained with Ponceau staining solution. 
8. The membrane was incubated with blocking solution for 1 hour in a rocker at 
room temperature. 
9. The membrane was then incubated with the primary antibody (Mouse anti-
GFP antibody) for 1 hour in a rocker at room temperature. 
10. The membrane was then washed with TBST four times with an interval of 10 
min each to remove the excess unbound antibodies. 
11. The membrane was incubated with secondary antibody 
(anti-mouse antibody) for 1 hour at room temperature in a rocker. 
12. The membrane was then washed with TBST four times with an interval of 10 
min each to remove the excess unbound antibodies. 
13. The membrane was given a final wash with IX TBS for 10 min in a rocker at 
room temperature. 
14. The blots were then exposed to Lumigen detection reagent - ECL plus reagent 
mixture (40:1 ratio) in dark and were incubated for 4 min at room 
temperature. 
15. The signals were then captured in X-ray films and they were then developed. 
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Hela Cell Line: 
HeLa cell lines of cervical cancer were brought from National Center for Cell Sciences, 
Pune, India. Cells were maintained in CO2 incubator maintained at 5% CO2 using RPMl 
1640 Growth medium. Gentamycin and fetal calf serum (10%) were used in culturing. 
Cells were harvested after fifth day and aliquots of the stock were kept in liquid nitrogen 
until use. The viability of the stock remained >99% at 1 year. Before use, aliquots were 
defrosted, followed by equilibration at 37°C for 45 minutes. 
Preparation of EGCG Solution: 
Epigallocatechin 3-gallate (EGCG) was purchased from Sigma, USA. The EGCG was 
dissolved in distilled water, after that EGCG solution was passed through the membrane 
(0.22 |im) filtered for in vitro uses. 
Preparation of RPMI-1640 medium: 
Dehydrated RPMI-1640 medium of one unit vial (16.3 gm) (HiMedia, India), was 
suspended in 950 ml of tissue culture-grade water at room temperature with constant, 
gentle stirring until the medium was completely dissolved. The container was rinsed with 
tissue culture grade water to remove all traces of powder and added to the above solution. 
3.7 gm sodium bicarbonate was added to the medium and stirred until dissolved. The 
final volume was brought to 1000 ml with tissue culture grade water. The medium was 
sterilized immediately by filtering through a sterile membrane filter with a porosity of 
0.22 micron using positive pressure rather than vacuum to minimize the loss of carbon 
dioxide, and stored at 4°C until use. 
Treatment with EGCG and viability assay: 
The effect of EGCG (0-80 \ig/m\) on the viability of HeLa cells was assessed by using 
MTT Cell Viability Assay Kit ( R & D Systems) according to the manufacture's 
instructions provided. 
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Reagents supplied in the kit: 
Component 
MTT reagent 
Detergent reagent 
Quantity 
25 ml 
250 ml 
Storage conditions 
2-8°C 
18-24°C 
Assay procedure: 
Adherent cells were gently scraped with RPMI-1640 medium. After this, 5 x 10^  
cells/well were seeded in 96-well flat-bottomed plates and allowed to attach overnight.. 
Cells were incubated in RPMI-1640 with 2% autologous serum containing EGCG (0, 20, 
40 and 80 ^g/ml) for 48 hours at 37°C, 10% CO2. After 48 hours, 10 ^l of MTT reagent 
(3-[4, 5-dimethylthiazol-2-yl]-2, 5-diphenyltetrazolium bromide) was added to each well 
and incubation was continued for an additional two hours. When a purple precipitate was 
clearly visible under the microscope, 100 yd of detergent reagent was added to all wells, 
including control wells and incubated for two hours in the dark at 20°C. After incubation, 
the precipitate was solubilized and the absorbance of the resulting solution was measured 
at 630 nm using a microplate reader. Control cells were treated exactly the same except 
that no EGCG was added to the wells. The percentage of viable cells was calculated by the 
formula as described by (Islam et al., 2000) and the results were expressed as "Viable cells 
(% of control cells)". 
Viable (% of control cells) 
Absorbance value of control cells 
x 100 
Absorbance value of treated cells 
39 
Trypan blue exclusion assay for Cell viability: 
The exponentially growing Hela cells were seeded onto 12-well, flat-bottomed plates at a 
density of SxloVmL and allowed to attach overnight. The cells were treated with the 
EGCG of varying concentration (0-80 ^g/ml) for 48hr at 37°C in a CO2 chamber (5%). 
The cells were collected by trypsinization and counted by a hemocytometer (Shanghai, 
China) under light microscope using the Trypan blue dye exclusion method for viability. 
The cells taking up Trypan blue (dead cells), and cells excluding the dye (viable cells) 
were counted. Percentage of viable cells was calculated by the following formula: 
Total viable cells (unstained) 
% Cell viability = x 100 
Total cells (stained plus unstained) 
Growth Kinetic Assay: 
Exponentially growing HeLa cells were seeded at 0.1 x 10^  cells/petri dish of 35 mm 
diameter for growth kinetics studies. Cells were treated with varying concentration of 
EGCG (0-80 |ig/ml) at 37°C for continuous exposure for 24 and 48hrs. Total cell number 
of untreated cells at time of treatment was taken as initial value (No). Cells were 
harvested at every 24 hrs time interval up to 48 hrs by trypsinization and counted using 
hemocytometer. For determining the proliferation (Nt/No), where, No is the total number 
of cells at treatment and Nt is the total number of cells at time t. Both floating and 
attached cells were counted and fixed in 80% chilled ethanol for cell cycle analysis. 
Cell cycle analysis: 
Progression of cells through different phases of cell cycle was also followed along with 
studies on cellular growth kinetics. Cells were washed with PBS by centrifugation at 
600g for 5 min, fixed in 80% chilled ethanol and store at 4°C till measurement. Flow 
cytometric measurement of cellular DNA content were performed with ethanol fixed 
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cells using the intercalating DNA fluorochrome, propidium iodide (PI) as described 
earlier (Zolzer et al., 1995). Briefly, the cells (0.5-1 million) were washed with PBS after 
removing ethanol and treated with of RNase A (200fig/ml) for 30 min at 37°C. 
Subsequently cells were stained with PI (25|jg/ml) for 15min at room temperature. 
Measurement were made with an argon laser-based Flowcytometer (FACS-Calibur 
Becton Dickinson San Jose, CA, USA) using the Argon laser (488nm) for excitation. 
Distribution of cells in different phases of cell cycle was calculated from the frequency 
distribution of D>JA content by using the Mod fit Programme (Variety Software, CA, 
USA). 
Annexin V binding: 
Apoptotic cells were detected by the labeling of externalized phosphotidyl serine using 
annexin V-FITC in unfixed cells (Verma and Mazumder., 1995). Following treatments 
cells were harvested and aliquots of 10^  cells resuspended in lOOfil binding buffer 
(lOmM HEPES/NaOH, PH 7.4, lOmM NaCl, 2.5mM CaCy and 5^1 Annexin V-FITC 
and lO i^l PI (50^g/ml) were added. After 15 min at room temperature 400|J1 of binding 
buffer were added to each sample and analyzed by flow cytometry. The percentage of 
Annexin V-positive and negative cells were estimated by applying appropriate gates and 
using regional statistics analysis facility provided in the cells Quest Software (Becton 
Dickenson, San Jose, CA, USA). 
Preparation of PBMC and treatment of monocytes culture 
Peripheral blood mononuclear cells (PBMCs) from blood of healthy donors and cervical 
cancer patients attending O. P. D. of J. N. Medical College and Hospitals, AMU, Aligarh 
were isolated by density gradient sedimentation on Ficoll-Paque separation medium as 
described by us earlier (Mesiter and Anderson, 1983; Hasan et al., 2006). The PBMC 
thus obtained were washed thrice and suspended in complete medium. By cytostaining, 
PBMC were comprised of 90% non-adherant lymphocytes and 10% adherent monocytes. 
Thereafter, PBMCs (5x10^ cells/well) were added in 12-well tissue culture plates (Costar 
Corp. Cambridge, MA) in complete RPMI-1640 medium, and were subsequently 
incubated at 37°C, 5% CO2 for 1-2 hrs for adherence, washed to remove non-adherant 
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cells and rested for overnight in RPMI-1640 medium having 2% autologous serum. Then, 
the adherent monocytes were co-cultured for 24 hrs with varying doses of EGCG (0-25 
|j,g/ml, dissolved in RPMI-1640 media). Cultures devoid of EGCG served as control. 
Also, some cultures were pre-treated with Z-VAD-FMK, Z-IETD-FMK and Z-LEHD-
FMK, which are known inhibitors of capase-3, caspase-8 and caspase-9 respectively. 
Following 24 hrs, the above cells were lysed for 30 min at 4°C in 0.5 ml of protein lysis 
buffer, which was prepared using MLB buffer (50 mM 3-(N-Morpholino)-
propanesulfonic acid (MOPS), pH 7.0, 250 mM NaCl, 5.0 mM EDTA, 0.1% NP-40 (a 
detergent), and 1.0 mM DTT) supplemented with protease inhibitors (1.0 mM PMSF, 5.0 
|xg/ml leupeptin, 10 mM NaF, 5.0 mM Na-pyrophosphate, 1.0 mM Na-orthovanadate, 
and 20 mM P-glycerophosphate). Thereafter, the suspension was centrifuged at 20,000 
rpm for 15 minutes at 4°C and supematants were stored at -20°C. Protein concentration 
was determined and the culture supematants were stored at -20°C until use. 
Caspase activity assay: 
Caspase-3, caspase-8 and caspase-9 related protease activity in cell lysates was 
determined as described elsewhere (Green and Reed, 1998; Ashkenazi and Dixit, 1998; 
Stennicke and Salvesen, 1998). The substrates employed were Asp-Glu-Val-Asp-p-
nitroanilide (DEVD-pNA) (Biomol.), Ac-Ile-Glu-Thr-Asp-pNA (lETD-pNA) and Ac-
Leu-Glu-His-Asp-pNA (LEHD-pNA) (Upstate Biotechnology, USA) for caspases-3, 8 
and 9 respectively. Caspase-3 inhibitor (Z-DEVD-FMK), caspase-8 inhibitor (Z-IETD-
FMK) and caspase-9 inhibitor (Z-LEHD-FMK) were from R & D Systems Europe 
(Abingdon, UK). Briefly, IxIO^ cells in 12-well plates were incubated with RPMI-1640 
medium containing EGCG (5 fig/ml) for 24 h. Thereafter, cells were lyzed in 80 |il of ice-
cold lysis buffer as described above. Twenty microliters of the supernatant was added to 
100 nl assay buffer containing 50 mM HEPES, 100 mM NaCl, 0.1% CHAPS, 10 mM 
DTT, 0.1 mM EDTA, 10% glycerol, pH 7.4. Ten microliters of respective caspase 
substrates were then added in the reaction system to final concentration of 0.2 mM. The 
cleavage of the substrate was monitored spectrophotometrically at 405nm and the 
activities were calculated according to the instruction of the manufacturer. 
42 
In order to determine the effects of specific caspase inhibitors on EGCG-induced 
apoptosis, Z-DEVD-FMK, Z-IETD-FMK and Z-LEHD-FMK were dissolved in DMSO 
as 20 mM stock solution and added to the culture medium to a final concentration of 50 
|iM as described earlier (Liu et al., 2002). After 2 hr pre-incubation, EGCG (5 ug/ml) was 
added and incubated for 24 h. The changes of EGCG-induced apoptosis in the presence of 
these inhibitors were determined as described. 
Cytomorphological and histomorphological effects of EGCG on cervical cancer 
biopsies: 
In the present study, biopsy pieces were taken directly from untreated cervical cancer 
patient (n=9) admitted for the first time and showing frank fungating growth. The 
Institutional Committee approved the study utilizing biopsies and blood collection. 
Biopsies from subjects showing differentiated keratinising and necrotising lesions were 
excluded from the study. Biopsy pieces were washed with buffered normal saline to 
remove debris, transferred to RPMI-1640 culture medium, bisected into 2 halves of 4-5 
mm size to serve as test and control. The samples in 15-ml Falcon tissue culture tubes 
were subjected to treatment without and with EGCG (5 jig/ml) and cultured at 37°C, 5% 
CO2 for 48 hrs. Thereafter, samples were processed for cytocentrifuged smear, and 
further processed for paraffin sections and staining. 
Glutathione peroxidase (GPx) assay: 
The activity of glutathione peroxidase (GPx) was measured as described elsewhere 
(Mohandas et al., 1984; Mates et al., 1999; Hasan et al., 2006). The oxidized glutathione 
(GSSG) produced during GPx reaction was immediately reduced by NADPH and 
glutathione reductase. Therefore, the rate of NADPH consumption was regarded as the 
rate of GSSG formation during the GPx reaction. Cancerous cell cultures as described 
above were co-cultured for 24 hours with or without 10 mM NAC and 0-80 |ag/ml 
EGCG. Thereafter, cells were gently scraped with lysis buffer containing protease 
inhibitors (50 mM Tris/HCl, pH 7.4; 1 mM EDTA; 500 mM PMSF). The cell suspension 
was homogenized with a sonicator on ice and centrifuged at 10,000 rpm for 10 minutes. 
Protein concentrations of supematants were determined by the method of Bradford with 
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BSA as the standard, and were subjected to GPx activity determination. The reaction 
mixture (1.0 ml) containing 50 mM potassium phosphate (pH 7.0), 1 mM sodium azide, 2 
mM GSH, 0.2 mM NADPH, 1 unit/ml glutathione reductase, 1.5 mM cumene 
hydroperoxide, and 20-100 \i\ of samples were incubated at 25°C for 5 minutes. The 
reaction was initiated by the addition of cumene hydroperoxide. The kinetic change was 
spectrophotometrically recorded at 340 nm (37°C) for 3 minutes. GPx activity was 
calculated after subtraction of the blank value, as ^mol of NADPH oxidized/minute/mg 
protein (U/mg protein). 
Statistical analysis: 
Results were analyzed by paired t-test and the data expressed as mean ± SEM of six 
experiments unless otherwise specified. P<0.05 was considered statistically significant. 
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The present study involves investigations for the effect of EGCG - a green tea 
polyphenol as well as a natural antioxidant on two cervical cancer model systems, 
which are: (a) monocytes ^ d biopsies from cervical cancer patients and (b) cervical 
cancer cell lines i.e. HeLa cell lines. Interesting data were generated, where, in 
summary, the model system involving monocytes and biopsies from cervical cancer 
patients showed high magnitude anti-inflammatory as well as apoptotic effect of 
EGCG (0-100 |ig/ml), while on the other hand, EGCG (0-100 |^g/ml) exerted high 
magnitude anti-inflammatory but low apoptotic effect on HeLa cell lines. The data 
obtained are discussed below under separate subheadings of the two model systems 
undertaken in the study. 
(A). STUDIES ON THE EFFECT OF ANTIOXIDANTS IN CERVICAL 
CANCER: 
As the active role-played by reactive oxygen species (ROS) in the cervical cancer is 
well established, thus an attempt was made in the present study to probe natural 
compounds having antioxidant properties in arresting ROS in cancer cells. Various 
workers on cervical cancer HeLa cell lines have extensively carried out such a study, 
but no or little work has been done on cervical cancer monocytes. Thus, comparative 
efficacy of natural antioxidants was carried out on cervical cancer monocytes versus 
HeLa cell lines. 
(i). Effect of EGCG on the GPx Activity of Healthy Control Human Monocytes: 
Prior to any study, an attempt was made first to evaluate the effect of EGCG on the 
GPx activity of healthy control human monocytes. Thus, normal healthy monocytes 
were co-cultured separately for 24 hours with varying doses of EGCG as described in 
methods. As evident from Figs. 7, in comparison to untreated cells, none of the doses 
of EGCG (0-50 (ig/ml showed any effect on the GPx activity. In fact, the GPx 
activities for untreated and treated normal healthy monocytes at various doses of 
EGCG were nearly the same (Figs. 7; n=3;p<0.001). 
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(ii). Dose Response Effect of EGCG on GPx Activity in 24 hr Cultures of 
Cervical Cancer Monocytes and HeLa Cell Lines: 
Thereafter, dose response effects of EGCG (0-50 ^g/ml) on GPx activity in 24 hr 
culture supematants of cervical cancer monocytes as well as HeLa cell lines were 
determined. In comparison to healthy control untreated monocytes in Fig. 7, the 
untreated cervical cancer monocytes exhibited an appreciable suppression by around 
2.14-folds in the GPx activity (Fig. 8; n=3;;7<0.001). However, as evident from Fig. 
8, co-culturing of cervical cancer monocytes with varying doses of EGCG exhibited 
appreciable amelioration in the GPx activity. The EGCG-mediated amelioration in the 
GPx activity was found to be of the order of 1.58-folds (/7<0.001), 1.8-folds 
(p<0.001), 1.9-folds (p<0.001), 1.97-folds (p<0.001), 2.02-folds (p<0.00\) and 2.01-
folds (p<0.00\) with 5,10, 20, 30,40 and 50 )xg/ml of EGCG respectively (Fig. 8). 
Next, an attempt was also made to probe the effect of varying doses of EGCG on the 
GPx activity in HeLa cell lines. When compared to healthy control untreated 
monocytes as illustrated in Fig. 7, the HeLa cell lines exhibited an appreciable 
suppression by around 1.98-folds in the GPx activity (Fig. 9; n=3; p<0.001). On the 
contrary, co-culturing of HeLa cell lines with varying doses of EGCG exhibited 
appreciable amelioration in the GPx activity. Computational analysis of the data in 
Fig 9, revealed that the EGCG-mediated amelioration in GPx activity was of the order 
of 1.27-folds (p<0.001), 1.52-folds (p<0.001), 1.66-folds (p<OM\), 1.76-folds 
(p<0.00l), 1.79-folds (p<0.001) and 1.79-folds (p<0.001) with 5,10, 20, 30, 40 and 50 
|ig/ml of EGCG respectively (Fig. 9). 
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FIGURE 7: Effect of EGCG on Healthy control human monocytes: Dose 
response effect of EGCG (0-50 |ag/nil) on 24 hr culture supematants of 
normal healthy monocytes. Data are mean (±S.E.) of 3 experiments. 
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(iii). Effect of NAC on the GPx Activity of Healthy Control Human Monocytes 
and HeLa Cell Lines: 
Next, was a known antioxidant i.e. N-Acetyl Cysteine (NAC) that was employed in 
the present study to detennine its effect on the GPx activity on healthy control human 
monocytes and HeLa cell lines. Normal healthy monocytes as well as HeLa cell lines 
were co-cultured separately for 24 hours with varying doses of NAC as described in 
methods. As evident from Figs. 10, in comparison to untreated cells, none of the doses 
of NAC (0-10 mM) showed any effect on the GPx activity. The GPx activities for 
untreated and treated normal healthy monocytes at various doses of NAC were nearly 
the same (Figs. 10; n=3;p<0.001). 
(iv). Dose Response Effect of N-Acetyl Cysteine (NAC) on GPx Activity in 24 hr 
Cultures of Cervical Cancer Monocytes and HeLa Cell Lines: 
Dose response effects of NAC (0-10 mM) on GPx activity in 24 hr culture 
supematants of cervical cancer monocytes as well as HeLa cell lines were determined 
in the present study. In comparison to healthy control untreated monocytes in Fig. 7, 
the untreated cervical cancer monocytes exhibited an appreciable suppression by 
around 2.12-folds in the GPx activity (Fig. 11; n=3;/7<0.001). However, as evident 
from Fig. 11, co-culturing of cervical cancer monocytes with varying doses of NAC 
exhibited appreciable amelioration in the GPx activity. The NAC-mediated 
amelioration in the GPx activity was found to be of the order of 1.15 -folds (p<0.00\), 
1.37-folds (/7<0.001), 1.46-folds (p<0.00\), 1.67-folds (p<0.00\) and 1.83-folds 
(p<0.001) with 2,4, 6, 8 and 10 mM of NAC respectively (Fig. 11). 
Thereafter, an attempt was also made to probe the effect of NAC (0-10 mM) on GPx 
activity in HeLa cell lines. Co-culturing of HeLa cell lines with varying doses of NAC 
exhibited appreciable amelioration in the GPx activity. Computational analysis of the 
data in Fig 12, revealed that the NAC-mediated amelioration in GPx activity was of 
the order of 1.15 -folds (p<0.001), 1.34-folds (p<0.001), 1.47-folds (p<0.001), 1.55-
folds (p<0.001) and 1.59-foIds (p<Om\) with 2, 4, 6, 8 and 10 mM of NAC 
respectively (Fig. 12). 
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(v). Effect of Curcumin on the GPx Activity of Healthy Control Human 
Monocytes: 
Next, an attempt was also made to evaluate the effect of Curcumin on the GPx 
activity of healthy control human monocytes. Normal healthy monocytes were co-
cultured separately for 24 hours with varying doses of Curcumin as described in 
methods. As evident from Figs. 13, in comparison to untreated cells, none of the doses 
of Curcumin (0-50 |ig/ml showed any effect on the GPx activity. GPx activities for 
untreated and treated normal healthy monocytes at various doses of Curcumin were 
nearly the same (Figs. 13; n=3;;?<0.001). 
(vi). Dose Response Effect of Curcumin on GPx Activity in 24 hr Cultures of 
Cervical Cancer Monocytes and HeLa Cell Lines: 
Next, a dose response effect of Curcumin (0-50 \ig/m\) on GPx activity in 24 hr 
culture supematants of cervical cancer monocytes as well as HeLa cell lines were 
determined in the present study. In comparison to healthy control untreated 
monocytes in Fig. 7, the untreated cervical cancer monocytes exhibited an appreciable 
suppression by around 2.12-folds in the GPx activity (Fig. 14; n=3;/?<0.001). 
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FIGURE 12: Effect of NAC on HeLa cell lines: Dose response effect of NAC (0-10 
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However, as evident from Fig. 8, co-culturing of cervical cancer monocytes with 
varying doses of Turmeric exhibited appreciable amelioration in the GPx activity, 
where the amelioration was found to be of the order of 1.21 -folds (p<0.00\), 1.41-
folds (p<0.001), 1.50-folds (p<0.001), 1.80-folds (p<0.001) and 1.78-folds (p<0.001) 
with 10, 20, 30,40 and 50 \ig/ml of Curcumin respectively (Fig. 14). 
Thereafter, effects of Curcumin (0-50 [ig/ml) on the GPx activity in HeLa cell lines 
were also probed. Co-culturing of HeLa cell lines with varying doses of Curcumin 
exhibited appreciable amelioration in the GPx activity. Computational analysis of the 
data in Fig 15, revealed that the Curcumin-mediated amelioration in GPx activity was 
of the order of 1.22 -folds (p<0.001), 1.28-folds (p<0.001), 1.42-folds (p<0.00\), 
1.50-folds (p<0.00\) and 1.61-folds (p<0.001) with 2, 4, 6, 8 and 10 mM of NAC 
respectively (Fig. 15). 
(vii). Effect of H2O2 on the GPx Activity of Healthy Control Human Monocytes: 
Next, an attempt was also made to probe the effect of H2O2 on the GPx activity of 
healthy control human monocytes. Thus, normal healthy monocytes were co-cultured 
separately for 24 hours with varying doses of H2O2 as described in methods. As 
evident from Fig. 16, in comparison to untreated cells, H2O2 was found to suppress the 
GPx activity linearly in a dose dependent manner. The H2O2 -mediated suppression 
was found to be of the order of 1.16 folds, 1.32-folds, 1.42-folds, 1.61-folds andl.66-
folds with 2, 4, 6, 8 and 10 nM of H2O2 respectively (Fig. 16; n=3;/?<0.001). 
(viii). Dose Response Effect of H2O2 on GPx Activity in 24 hr Cultures of 
Cervical Cancer Monocytes and HeLa Cell Lines: 
Thereafter, dose response effects of H2O2 (0-10 nM) on GPx activity in 24 hr culture 
supematants of cervical cancer monocytes as well as HeLa cell lines were determined. 
In comparison to healthy control untreated monocytes in Fig. 7, the untreated cervical 
cancer monocytes exhibited an appreciable suppression by around 2.14-folds in the 
GPx activity (Fig. 17; n=3;/?<0.001). 
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FIGURE 15: Effect of Curcumin on HeLa cell lines: Dose response effect of 
Curcumin (0-50 |J.g/ml) on 24 hr culture supernatants of HeLa cell 
lines. Data are mean (±S.E.) of 3 experiments. (p<0.001). 
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FIGURE 16: Effect of Hydrogen peroxide (H2O2) on Healthy control human 
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However, as evident from Fig. 17, co-cuituring of cervical cancer monocytes with 
varying doses of H2O2 exhibited a further suppression in the GPx activity. The H2O2-
mediated further suppression in the GPx activity was found to be of the order of 1.25-
folds (p<0.001), 1.59-folds (p<0.001), 1.96-folds (p<0.001), 2.05-folds (p<0.001) and 
2.32-folds (/?<0.001) with 2,4, 6, 8 and 10 nM of H2O2 respectively (Fig. 17). 
Next, an attempt was also made to probe the effect of varying doses of H2O2 on the 
GPx activity in HeLa cell lines. When compared to healthy control untreated 
monocytes as illustrated in Fig. 7, the HeLa cell lines exhibited an appreciable 
suppression by around 1.98-folds in the GPx activity (Fig. 18; n=3; p<0.001). On the 
contrary, co-culturing of HeLa cell lines with varying doses of H2O2 exhibited further 
suppression in the GPx activity. Computational analysis of the data in Fig 18, 
revealed that the H202-mediated further suppression in GPx activity was of the order 
of 1.19-folds (p<0.001), 1.53-folds (p<0.00\), 2.2-folds (p<0.00\), 2.27-folds 
(p<0.001) and 2.39 -folds (p<0.00\) with 2, 4, 6, 8 and 10 nM of H2O2 respectively 
(Fig. 18). 
(B). Model System - Healthy Monocytes: Competitive Effect of Hydrogen 
peroxide (H2O2) (10 nM) versus EGCG (20 fig/ml), NAC (10 mM) and Curcumin 
(20 ^g/ml) on the GPx activities in healthy control human monocytes. 
After observing the role of hydrogen peroxide (H2O2) and EGCG- a green tea 
polyphenol as well as a natural antioxidant as a positive and negative regulator 
respectively of GPx activity, an attempt was also made to probe the competitive effect 
of the above said positive regulator versus negative regulator present in the same cell 
culture. Thus, normal healthy monocytes were co-cultured separately for 24 hours 
with lOnM of H2O2 along with 20 |ig/ml of EGCG. As evident from Fig. 19, addition 
of lOnM of H2O2 showed a down-regulation in the GPx activity by ~1.66-folds (n=3; 
p<0.00\) in comparison to untreated healthy monocytes. However, healthy monocytes 
cultures receiving H2O2 along with EGCG showed interesting results. EGCG here was 
found to ameliorate by ~1.42-folds (n=3; ;7<0.001) the H202-mediated suppressed 
GPx activity. 
61 
Hydrogen peroxide (H2O2), (nM) 
10 
FIGURE 18: Effect of Hydrogen peroxide (H2O2) on HeLa Cell Lines: Dose 
response effect of H2O2 (0-10 nM) on 24 hr culture supematants of 
HeLa cell lines. Data are mean (±S.E.) of 3 experiments. (p<0.00]). 
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Next, after EGCG, an attempt was also made to probe the competitive effect H2O2 
versus NAC and Curcumin on the GPx activity in healthy monocytes. Both, NAC and 
Curcumin are proven antioxidants. As evident from the data, 10 mM NAC and 20 
^g/ml Curcumin were found to ameliorate by -1.31-folds (Fig. 20; n=3;p<0.001) and 
~ 1.38-folds (Fig. 21; n=3;p<0.001) respectively the suppressed GPx activity in H2O2 
treated healthy monocytes. 
Thus, analysis of the data in Fig 19-21, it was observed that the capability of 
ameliorating the suppressed GPx activity in healthy monocytes due to H2O2 treatment 
was found to be of the order of EGCG (~1.42-folds) > Curcumin (~1.38-folds) > 
NAC (-1.31-folds). 
(C). Model System - Cervical Cancer Monocytes: Competitive Effect of 
Hydrogen peroxide (H2O2) (10 nM) versus EGCG (20 ^ig/ml), NAC (10 mM) and 
Curcumin (20 ^g/ml) on the GPx activities in cervical cancer monocytes. 
Next, the model system for competitive probe was cervical cancer monocytes. Thus, 
cervical cancer monocytes were co-cultured separately for 24 hours with lOnM of 
H2O2 along with 20 )ig/ml of EGCG. As evident from Fig. 22, a suppressed the GPx 
activity by ~2.22-folds (n^3; p<0.001) was observed in cervical cancer monocytes 
was observed in comparison to healthy control monocytes (Fig. 21). The suppressed 
GPx activity in untreated cervical cancer monocytes was further suppressed by ~ 
2.32-folds (Fig. 22; n=3; ;7<0.001) by the addition of lOnM of H2O2. However, 
cervical cancer monocytes cultures receiving H2O2 along with EGCG showed 
amelioration by ~3.64-folds (Fig. 22; n=3;/7<0.001) in the H202-mediated suppressed 
GPx activity. 
Next, an attempt was also made to probe the competitive effect H2O2 versus NAC and 
Curcumin on the GPx activity in cervical cancer monocytes. As evident from the data, 
10 mM NAC and 20 ^ig/ml Curcumin were found to ameliorate by ~3.09-folds (Fig. 
23; n=3; p<0.00\) and - 3.37-folds (Fig. 24; n=3; j!?<0.001) respectively the 
suppressed GPx activity in H2O2 treated cervical cancer monocytes. 
Thus, analysis of the data in Fig 16-18, it was observed that the capability of 
ameliorating the suppressed GPx activity in cervical cancer monocytes due to H2O2 
treatment was found to be of the order of EGCG (-3.64-folds) > Curcumin (-3.37-
folds)>NAC(~3.09-folds). 
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FIGURE 20: Healthy Control Monocytes: Competitive Effect of Hydrogen 
peroxide (H2O2) (10 nM) versus NAC (10 mM) on GPx activity in 
healthy control human monocytes: Data are mean (±S.E.) of 3 
experiments. (p<0.00\). 
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FIGURE 21: Healthy Control Monocytes: Competitive Effect of Hydrogen 
peroxide (H2O2) (10 nM) versus Curcumin (20 |ig/ml) on GPx 
activity in healthy control human monocytes: Data are mean (±S.E.) 
of 3 experiments. (p<0.001). 
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FIGURE 22: Cervical Cancer Monocytes: Competitive Effect of Hydrogen 
peroxide (H2O2) (10 nM) versus EGCG (20 |ag/ml) on GPx activity 
in cervical cancer monocytes: Data are mean (±S.E.) of 3 
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FIGURE 23: Cervical Cancer Monocytes: Competitive Effect of Hydrogen 
peroxide (H2O2) (10 nM) versus NAC (10 mM) on GPx activity in 
cervical cancer monocytes: Data are mean (±S.E.) of 3 experiments. 
(p<0.001). 
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FIGURE 24: Cervical Cancer Monocytes: Competitive Effect of Hydrogen 
peroxide (H2O2) (10 nM) versus Curcumin (20 |ig/ml) on GPx 
activity in cervical cancer monocytes: Data are mean (±S.E.) of 3 
experiments. (p<0.001). 
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(D). Model System - HeLa Cell Lines: Competitive Effect of Hydrogen peroxide 
(H2O2) (10 nM) versus EGCG (20 fig/ml), NAC (10 mM) and Curcumin (20 
ftg/ml) on the GPx activities in HeLa cell lines. 
Thereafter, the next model system for competitive probe was HeLa cell lines. Thus, 
HeLa cell lines were co-cultured separately for 24 hours with lOnM of H2O2 along 
with 20 }ig/ml of EGCG. As evident from Fig. 25, a suppressed the GPx activity by 
~2.06-folds (n=3; p<0.00\) was observed in HeLa cell lines was observed in 
comparison to healthy control monocytes (Fig. 21). The suppressed GPx activity in 
untreated cervical cancer monocytes was further suppressed by ~ 2.34-folds (Fig. 25; 
n=3; p<0.001) by the addition of lOnM of H2O2. However, HeLa cell line cultures 
receiving H2O2 along with EGCG showed amelioration by -3.21-folds (Fig. 25; n=3; 
p<0.001) in the H202-mediated suppressed GPx activity. 
Next, an attempt was also made to probe the competitive effect H2O2 versus NAC and 
Curcumin on the GPx activity in HeLa cell lines. As evident from the data, 10 mM 
NAC and 20 |ig/ml Curcumin were found to ameliorate by ~2.95-folds (Fig. 26; n=3; 
p<0.00\) and ~ 3.05-folds (Fig. 27; n=3; p<0.001) respectively the suppressed GPx 
activity in H2O2 treated HeLa cell lines. 
Analysis of the data depicted in Fig 25-27, showed that the capability of ameliorating 
the suppressed GPx activity in HeLa cell lines due to H2O2 treatment was found to be 
of the order of EGCG (~3.21-folds) > Curcumin (~3.05-folds) > NAC (~2.95-folds). 
(i). Glutathione peroxidase activity 
Glutathione peroxidase (GPx) activity was determined in 24 hr culture supematants of 
cervical cancer monocytes (CC MN) and HeLa cell lines that were cultured for 24 hrs 
without and with either EGCG (20 ^ig/ml), NAC (10 mmol/1) and Curcumin (20 
[xg/ml). GPx activity was determined in culture supematants at 24 h. Healthy human 
monocyte cultures served as controls. As evident from Fig. 28, cervical cancer 
monocytes and HeLa cell lines showed suppressed GPx activity in comparison to 
healthy control monocytes. However, co-culturing the above cancerous cells with 
EGCG, NAC or Curcumin resulted in amelioration of GPx activity. The order of 
amelioration of GPx activity was EGCG > NAC > Curcumin, and that, the 
amelioration capacity of EGCG was somewhat stronger in cervical cancer monocytes 
than in HeLa cell lines. 
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FIGURE 25: HeLa Cell Lines: Competitive Effect of Hydrogen peroxide (H2O2) (10 
nM) versus EGCG (20 ng/ml) on GPx activity in Hela cell lines. Data 
are mean (±S.E.) of 3 experiments. (p<0.001). 
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FIGURE 26: HeLa Cell Lines: Competitive Effect of Hydrogen peroxide (H2O2) (10 
nM) versus NAC (10 mM) on GPx activity in HeLa cell lines. Data are 
mean (±S.E.) of 3 experiments. (p<0.001). 
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FIGURE 27: HeLa Cell Lines: Competitive Effect of Hydrogen peroxide (H2O2) (10 
nM) versus Curcumin (20 ng/ml) on GPx activity in HeLa cell lines. 
Data are mean (±S.E.) of 3 experiments. (p<0.001). 
73 
100 
Healthy Monocytes as well as untreated and treated 
cervical cancer monocytes and HeLa cell lines 
FIGURE 28: Determination of Glutathione peroxidase (GPx) activity. Cervical 
cancer monocytes (CC MN) and HeLa cell lines were cultured for 24 
hrs without and with either EGCG (20 ng/ml), NAC (10 mmol/1) and 
Curcumin (20 |xg/ml). GPx activity was determined in culture 
supematants at 24 h. Healthy human monocyte cultures served as 
controls. Data are mean (±S.E.) of 5 experiments. (p<0.00\ for all). 
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(ii). Caspase Assay: Effect of EGCG on Caspases-3, 8 and 9 in 24 hr culture 
supernatants of cervical cancer monocytes and HeLa cell lines. 
Induction of EGCG-induced apoptosis was ascertained by measuring the activity of 
caspase-3, caspase-8 and caspase-9-like proteases in EGCG treated and untreated 
monocytes from cervical cancer patients as well as HeLa cell lines. 
Monocyte and HeLa cell line cultures treated with EGCG and cultured for 24 hrs 
exhibited significantly higher activity of caspase-3 followed by caspase-8 and 
caspase-9 like proteases, thereby indicating that the activation of caspase-3 like 
proteases was associated with reduced cell survival and apoptotic death of EGCG-
treated cervical cancer monocytes and HeLa cell lines (Figs. 41-46). 
Cervical cancer monocytes and HeLa cell lines devoid of any EGCG treatment 
exhibited a caspase-3 activities to the order of only 5.88 pMol unit hydrolyzed/minute 
and 6.39 pMol unit hydrolyzed/minute respectively (Figs. 29 and 30; n=5; p<0.00\ 
for both). On the contrary, co-culturing with 20 |ig/ml of EGCG, the caspase-3 
activities in cervical cancer monocytes and HeLa cell lines was found to be of the 
order of 134.96 pMol unit hydrolyzed/minute and 193.87 pMol unit 
hydrolyzed/minute respectively (Figs. 29 and 30; n=5;p<0.001 for both). 
Thereafter, an attempt was made to assess the effect of EGCG on caspase-8. Cervical 
cancer monocytes and HeLa cell lines devoid of any EGCG treatment exhibited 
caspase-8 activities be of the order of only 2.93 pMol unit hydrolyzed/minute and 
4.70 pMol unit hydrolyzed/minute respectively (Figs. 31 and 32; n=5; p<OM\ for 
both). On the contrary, co-culturing with 20 i^ g/ml of EGCG, the caspase-8 activities 
in cervical cancer monocytes and HeLa cell lines was found to be of the order of 
109.24 pMol unit hydrolyzed/minute and 153.35 pMol unit hydrolyzed/minute 
respectively (Figs. 31 and 32; n=5;/?<0.001 for both). 
Next, an attempt was made to assess the effect of EGCG on caspase-9. Monocytes 
from patients with cervical cancer and HeLa cell lines devoid of any EGCG treatment 
exhibited caspase-9 activities to be of the order of only 2.62 pMol unit 
hydrolyzed/minute and 5.74 pMol unit hydrolyzed/minute respectively (Figs. 33 and 
34; n=5;/7<0.001 for both). On the contrary, co-culturing with 20 |ig/ml of EGCG, the 
caspase-9 activities in cervical cancer monocytes and HeLa cell lines was found to be 
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of the order of 49.64 pMol unit hydrolyzed/minute and 69.62 pMol unit 
hydrolyzed/minute respectively (Figs. 33 and 34; n=5;;7<0.001 for both). 
The above apoptotic effect of EGCG was further ascertained by the resuhs obtained 
from cervical cancer monocytes and Hela cell lines that were pre-treated with cell 
permeable inhibitor Z-VAD-FMK (caspase-3 inhibitor), Z-IETD-FMK (caspase-8 
inhibitor) and Z-LEHD-FMK (caspase-9 inhibitor) followed by EGCG for 24 hrs 
(Figs 35-37; p<0.001 for all). In this case, the cell viability assay showed that the 
presence of Z-VAD-FMK inhibitor blocked the effect of EGCG on the viability of 
cancer monocytes. 
(iii). Effect of varying doses of EGCG on the viability of cervical cancer 
monocytes 
To probe that whether EGCG affects the viability of cervical cancer cells, monocytes 
from randomly selected cervical cancer patients (n=3) as well as HeLa cell lines (n=3) 
were treated with varying doses (0 -20 fig/ml) of EGCG and cultured for 24 and 48 
hors respectively. Thereafter, MTT assay determined the cell viability. The cell 
viability data is expressed as percent mean viable cells compared to untreated cells 
(taken as 100% viable) at different doses of EGCG. Our results show that EGCG were 
potent inhibitor of cell proliferation and the cell viability was around 50.01%, 
38.11%, 31.23% and 26.12% after 24 hrs of treatment with 5, 10, 15 and 20 |ag/ml of 
EGCG respectively (Fig. 38). Based on this data (p<0.001 for all), EGCG was used at 
a concentration of 5 \xg in subsequent experiments as this concentration produced 
high magnitude inhibition in cell proliferation when compared to controls. On the 
contrary, HeLa cell lines co-cultured with EGCG showed negligible or low magnitude 
effects when harvested after 24 hours. 
Thereafter, attempts were also made to assess the time-dependent EGCG induced 
effects on both cervical cancer monocytes as well as HeLa cell lines i.e. after 48 hrs of 
culture. The cell viability of cervical cancer monocytes treated for 48 hrs with varying 
doses of EGCG was recorded to be around 41.23%, 29.23%, 24.33% and 21.39% 
with 5, 10, 15 and 20 ^g/ml of EGCG respectively (Fig. 34; n=3; p<0.001 for all). 
After 48 hrs of EGCG treatment, HeLa cell lines showed appreciable effects. The cell 
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viability of HeLa cell lines treated for 48 hrs with varying doses of EGCG was found 
to be around 80.27%, 64.44%, 58.05% and 55.13% with 5, 10, 15 and 20 ^g/ml of 
EGCG respectively (Fig. 39; n=3;/?<0.001 for all). Thus, comparative computational 
analysis of the data depicted in Fig. 39, exhibited EGCG to reduce the viability 1.95 
folds, 2.20 folds, 2.39 folds and 2.58 folds more effectively in cervical cancer 
monocytes in comparison to HeLa cell lines with 5, 10, 15 and 20 ng/ml of EGCG 
respectively. Similar observations were made with Trypan blue e x p l ^ ^ ^ ^ s a ^ ^ ' t ^ X 
>(ACC. N« ) f I 
(iv). Western Blot for PARP cleavage and Bcl-2 expression V*^^. '^"^J 
It is well established that PARP, the zinc-dependent DNA binding protein that 
specifically recognizes DNA strand breaks, is cleaved by caspase-3, and the cleavage 
of PARP is regarded as a specific marker of apoptosis (Rukmini et al., 2004, Islam et 
al., 2000) To confirm the apoptotic effects of EGCG in cervical cancer monocytes, a 
western blot was performed to examine the PARP cleavage. We observed that in 
EGCG (20ug/ml) treated cells, the content of the intact form (113 kDa) of PARP was 
decreased and its 89 kDa cleaved fragment was increased (Fig. 41). No changes were 
observed when samples were blotted by anti-B-actin (Fig. 41). Also, high dose of 
EGCG (80 |ig/ml) affected the Bcl-2 expression in HeLa cell lines at both 24 hrs and 
48hrs (Fig. 42), and that, this is in accordance to our results obtained for Cell Cycle 
Analysis and FITC-Annexin-V Assay depicted below. 
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FIGURE-29: Caspase-3 activity assay: In 24 hr supernatant of monocyte culture 
from cervical cancer patient that were either treated with or without 20 
\ig/ml of EGCG (p<0.001). Data represents mean ± SEM of 10 
experiments. 
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FIGURE-30: Caspase-3 activity assay: In 24 hr supernatant of HeLa cell lines 
culture that were either treated with or without 20 ^g/ml of EGCG 
(p<0.00l). Data represents mean ± SEM of 10 experiments. 
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FIGURE-31: Caspase-8 activity assay: In 24 hr supernatant of monocyte culture 
from cervical cancer patient that were either treated with or without 20 
|xg/ml of EGCG (p<0.001). Data represents mean ± SEM of 10 
experiments. 
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FIGURE-32: Caspase-8 activity assay: In 24 hr supernatant of HeLa cell lines 
culture that were either treated with or without 20 \xg/m\ of EGCG 
(p<0.00\). Data represents mean ± SEM of 10 experiments. 
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FIGURE-33: Caspase-9 activity assay: In 24 hr supernatant of monocyte culture 
from cervical cancer patient that were either treated with or without 20 
^g/ml of EGCG (p<0.001). Data represents mean ± SEM of 10 
experiments. 
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FIGURE 34: Caspase-9 activity assay: In 24 hr supernatant of HeLa cell lines 
culture that were either treated with or without 20 i^g/ml of EGCG 
(p<0.001). Data represents mean ± SEM of 10 experiments. 
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FIGURE-35: A comparative analysis of Caspase-3 expression in Cervical Cancer 
monocyte and HeLa cell lines treated with EGCG (lined bar) and an 
inhibitor of Caspase-3 (Black bar). Data represents mean ± SEM of 3 
experiments 
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FIGURE-36: A comparative analysis of Caspase-8 expression in Cervical Cancer 
monocyte and HeLa cell lines treated with EGCG (lined bar) and an 
inhibitor of Caspase-8 (Black bar). Data represents mean ± SEM of 3 
experiments. 
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FIGURE-37: A comparative analysis of Caspase-9 expression in Cervical Cancer 
monocyte and HeLa cell lines treated with EGCG (lined bar) and an 
inhibitor of Caspase-9 (Black bar). Data represents mean ± SEM of 3 
experiments. 
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FIGURE 38: MTT cell viability assay: For dose response effect of EGCG (0-20 
|j.g/ml) after 24 hr on cervical cancer monocytes (plz note: in HeLa cell 
line at 24 hr negligible effect of EGCG was observed). Data represents 
mean ± SEM of 3 experiments. 
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FIGURE 39: MTT cell viability assay: For dose response effect of EGCG (0-20 
|ig/ml) after 48 hr on cervical cancer monocytes (blue bar) and HeLa 
cell line (grey bar). Data represents the analysis of three independent 
experiments in duplicate, expressed as mean viable cells (± SEM) 
percentage of controls. 
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FIGURE-40: Trypan blue cell viability assay: Viability of HeLa cells following 
EGCG treatment. HeLa cells were incubated with EGCG (0-80 |ig/ml 
48hr) and the number of viable cells is counted by trypan blue 
exclusion assay. Cell viability is represented as percent viable cells, 
where the vehicle treated cells are regarded as 100%. Data represents 
the analysis of three independent experiments in duplicate, expressed 
as mean viable cells (± SEM) percentage of controls. 
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FIGURE 4: Immunoblot Analysis of PARP cleavage: the HeLa cell lysate was 
prepared following treatment and 50 |j,g of protein was subjected to 12% 
tris glycine gel electrophoresis, followed by immunoblot analysis and 
chemiluminescence detection. Lane#l = untreated control cancer cells; 
Lane#2 = EGCG-treated cancer cells showing PARP cleavage (113 kDa 
i.e. upper row and 89 kD i.e. lower row).The data shown here are from a 
representative experiment repeated three times with similar results. 
90 
Cont 24hr 48 hr 
Bcl-2 
pactin 
Figure 42: Western blot: Effect of EGCG on protein expression of bcl-2 in HeLa 
cell line. The cells were treated with Vehicle or EGCG (80 ng/ml for 24 
and 48hr), and then harvested. Total cell lysate were prepared and 50ug 
protein was subjected to SDS-Page followed by Western blot analysis 
and chemiluminescent detection. Data shown below the blots represents 
fold modulation in protein expression normalized to |3-actin. The data 
shown here are from a representative experiment repeated three times 
with similar results. 
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(v) Growth kinetic analysis 
The growth kinetic analysis was carried out to investigate the antiproliferative effect 
of EGCG. In this study, HeLa cell lines were co-cultured with 0-80 ng/ml of EGCG 
for 24 and 48hrs. The growth analysis curves depicted in Fig. 43 exhibited a marginal 
decrease in proliferation rate (Nt/No) at 24 hrs. On the contrary, at 48hrs, this decrease 
in proliferation of cell became more significant / more appreciable in a dose-
dependent manner (Fig. 43). Thus, the results obtained are in accordance to our 
observations made in the above cell viability assays at 48 hrs. 
(vi). Cell Cycle Analysis and FITC-Annexin V Assay 
As we all know that, cells proceeds from Gi - S -G2 but after G2 cells undergo mitosis 
and cell proliferates. In this study we were keen to observe the effect of EGCG on 
these dividing cells. As evident from Fig. 44, it was observed that at 80 |ig/ml of 
EGCG, there is cell arrest at G2/M phase of cell cycle, the number of cell at this phase 
were significantly increases at 48hr which is correlated with the growth kinetics of 
cells at the same time point. This arrest may due to DNA damage or by some other 
reasons but DNA damage is the most evident cause of cell arrest at G2/M phase. At 10 
and 20 |xg/ml concentration there was no significant changed was observed at all the 
time point (data not shown). The increase in sub Gl population of cells at 48 hrs by 
EGCG (40 and 80 |ig/ml) treatment also indicates the apoptotic cell death, which is 
further confirmed by Annexin-V assay (Fig. 45). 
(vii). Effect of EGCG on cytomorphological and histomorphological appearance 
of cervical carcinoma (biopsy) and HeLa cell lines 
Cytomorphological investigation for the appearance of carcinoma cells co-cultured 
along with 20 ^g/ml of EGCG (Fig.46) show better differentiation of nuclear and 
cellular outlines as well as increased eosinophilia of cytoplasm along with compact 
and condensed chromatin as compared to cells devoid of any EGCG (Fig. 47) (PAP X 
400). Also, effects of EGCG on non-neoplastic ectocervical cytosmears was probed 
where enhanced keratanization process in comparison to control samples devoid of 
EGCG was observed, and that, no apoptotic cells were observed (data not shown). 
Histomorphological data showed that in comparison to carcinoma cells devoid of any 
EGCG treatment (Fig. 48), co-culturing with EGCG (20 ^ig/ml) resulted in augmented 
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eosinophilia of the cytoplasm along with apoptotic body (arrow) having pyknotic 
nucleus and dense eosinophilic cytoplasm (Fig. 49) (H&E X 400). Similar 
observations were made in HeLa cell lines (Fig. 50). 
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Figure 43: Proliferation Rate by Flow cytometer: HeLa cell were treated with 
Vehicle or varying concentrations of epigallocatechin gallate for 24 and 48 
hr, and analysed by flow cytometry. The data shown here are from a 
representative experiment repeated three times with similar results. At 10 
and 20 |ag/ml effect are negligible (Data not shown). 
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Figure 44: Cell cycle analysis by Flow cytometer: HeLa cell were treated with 
Vehicle or epigallocatechin gallate (40 & 80 fig/ml) for 24 and 48 hr, and 
analysed by flow cytometry. The data shown here are from a 
representative experiment repeated three times with similar results. At 10 
and 20 ng/ml effect are negligible (Data not shown). 
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Figure-45: Apoptotic analysis by Annexin-V FITC: Dose and time dependent 
quantification of apoptosis in HeLa by flow cytonaetry. Cells were 
treated at the indicated dose and time with EGCG, labeled with Annexin-
V FITC and PI by using an apoptosis kit followed by flow cytometry. At 
the concentration of 10 ^ig/rnl, effects are negligible (Data not shown). 
The data shown here are from a representative experiment repeated three 
times with similar results. 
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FIGURE 46: Effect of EGCG on cytomorphological investigation for the appearance 
of carcinoma cells co-cultured along with 20 ^ig/ml of EGCG. 
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Figure 47: Effect of EGCG on cytomorphological appearance show better 
differentiation of nuclear and cellular outlines as well as increased 
eosinophilia of cytoplasm along with compact and condensed 
chromatin as compared to cells devoid of any EGCG (Fig. 46A) (PAP 
X 400). 
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Figure 48: Histomorphological data showed that in comparison to carcinoma cells 
devoid of any EGCG treatment. 
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Figure 49: Histomorphological data showed that in comparison to carcinoma cells 
co-culturing with EGCG (20 |ag/ml) resulted in augmented eosinophilia 
of the cytoplasm along with apoptotic body having pyknotic nucleus and 
dense eosinophilic cytoplasm (Fig. 47A) (H&E X 400). 
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FIGURE 50: Morphological analysis of HeLa cell lines treated with EGCG (A) 
Monolayer of HeLa Cell line (B) Control at 48hr.(C&D)-Treated with 40 & 80 
(^ ig/ml) EGCG at 48 hr, picture were taken by using a phase contrast microscope at 
400X magnification. The data shown here are from a representative experiment 
repeated three times with similar results. 
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VlSCV-SSIOn 
Globally, cervical cancer takes the lives of more than 250000 women each 
year, particularly in under-resourced areas of low-, middle-, and high-income 
countries. Options for cancer control and treatment have reached a point that there are 
interventions for control that could be adopted for virtually every resource and 
demographic situation (Cain et al , 2009). Women die despite the availability of 
attractive control options, which means that educating policy makers, women's health 
professionals, as well as women themselves, must become a major focus for ongoing 
control of this disease. The human right to life, to prevention of suffering, and to 
education are all key rights linked to improving the control of cervical cancer and 
saving the lives of women, particularly in resource-poor parts of the world (Cain et. 
al., 2009). 
Emerging evidence demonstrates that targeting the tumor proteasome is a 
promising strategy for cancer therapy (Yang et al., 2009). Results about the clinical 
application of specific proteasome inhibitors and natural products with proteasome-
inhibitory activity for cancer prevention or therapy have been reviewed (Yang et al., 
2009). Bortezomib, the reversible proteasome inhibitor that first entered clinical trials, 
has been studied extensively as a single agent and in combination with 
glucocorticoids, cytotoxic agents, immunomodulatory drugs and radiation as 
treatment for multiple myeloma and other hematological malignancies. There is less 
evidence of bortezomib's efficacy in solid tumors. Novel irreversible proteasome 
inhibitors, NPI-0052 and carfilzomib, have also been developed and clinical trials are 
underway therapy (Yang et al., 2009). Natural products with proteasome-inhibitory 
effects, such as green tea polyphenol (-) epigallocatechin-3-gallate (EGCG), soy 
isoflavone genistein, and the spice turmeric compound curcumin, have been studied 
alone and in combination with traditional chemotherapy and radiotherapy against 
various cancers. There is also interest in developing these natural compounds as 
potential chemopreventive agents (Yang et al., 2009). Thus, in the present study, 
EGCG - a natural antioxidant was employed to explore the potential chemopreventive 
mechanism in cervical cancer. 
The major constituents of green tea are the Flavan-3-ols (catechins) that 
include (-)-epigallocatechin-3-gallate (EGCG), (-)-epigallocatechin (EGC), (-)-
epicatechin-3-gallate (ECG), and (-)-epicatechin (EC). These polyphenol compounds 
have antioxidative and anti-mutagenic properties. A variety of antioxidants and 
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chemopreventive agents are cytotoxic to cancer cells. Cellular growth inhibition by 
green tea has been established in many tumor cells where EGCG has been a prime 
candidate for mediating this effect. Recently, anti-proliferative and anti-cancer action 
of EGCG has been reported in cancer cell lines (Ji et al., 2006; Pasckha et al., 1998; 
Blatter and Virji, 2000; Jung et al., 2001; Ahn et al., 2003; Huh et al., 2004). A vast 
variety of naturally occurring substances are known to protect against experimental 
carcinogenesis. It is becoming increasingly evident that certain phytochemicals, 
particularly those included in our daily diet, may have important cancer 
chemopreventive properties (Sanaha et al , 1997). Some anti-inflammatory 
chemopreventive agents have been found to suppress growth and proliferation of 
transformed or malignant cells through induction of programmed cell death or 
apoptosis (Bellosillo et al., 1998). 
Regarding EGCG, population-based and clinical studies indicate that the 
antioxidant properties of green tea may help prevent atherosclerosis, particularly 
coronary artery disease. It has been reported that 70% EGCG is a potent tool in 
nutritional arsenal not only as an antioxidant, but to address arterial inflammation. 
Highly sensitive C-reactive protein (hs-CRP) is a marker of arterial inflammation. 
Inflammation is also believed to play a role in heart disease; EGCG is a potent anti-
inflammatory. According to Japanese research, green tea reduces the levels of LDL or 
'bad' blood cholesterol, thereby reducing the risk of coronary heart disease. Research 
also indicates that tea polyphenols may reduce the activity of platelets, which are the 
clotting agents of the blood. This is good, because 'sticky' blood is more likely to form 
artery-blocking clots. Green tea has demonstrated an ability to lower total cholesterol 
and raise HDL ("good") cholesterol in both animals and people. This suggests that 
polyphenols in green tea may block the intestinal absorption of cholesterol and 
promote its excretion from the body. EGCG has been reported to inhibit lipid 
peroxidation, an oxidative process implicated in several pathologic conditions, 
including atherosclerosis. It has been suggested that EGCG and other tea catechins 
suppress tumor promotion by inhibiting the release of tumor necrosis factor-alpha, 
which is believed to stimulate tumor promotion and progression of initiated cells as 
well as premalignant cells Furthermore, EGCG was shown to reduce specific binding 
of both the 12-Otetradecanoylphorbol-13-acetate (TPA)-type and the okadaic acid-
type tumor promoters (the two major classes of tumor-promoting agents) to their 
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receptors. An EGCG act against urokinase, an enzyme often found in large amounts 
in human cancers, inhibits ornithine decarboxylase (a rate-limiting enzyme closely 
associated with tumor promotion), and blocks type-1 Salpha-reductase (5AR). 
Inhibitors of 5AR may be effective in the treatment of 5 alpha dihydrotestosterone-
dependent abnormalities, such as benign prostate hyperplasia, prostate cancer, and 
certain skin diseases. EGCG, inhibits tumor growth by inhibiting VEGF induction in 
human colon carcinoma cells. In the in vitro studies, (-)-epigallocatechin gallate 
(EGCG) inhibited Erk-1 and Erk-2 activation in a dose-dependent manner. However, 
other tea catechins such as (-)-epigallocatechin (EGC), (-)-epicatechin gallate (ECG), 
and (-)-epicatechin (EC) did not affect Erk-1 or 2 activation at a concentration of 30 
M. EGCG also inhibited the increase of VEGF expression and promoter activity 
induced by serum starvation. In the in vivo studies, athymic BALB/c nude mice were 
inoculated subcutaneously with HT29 cells and treated with daily intraperitoneal 
injections of EC (negative control) or EGCG at 1.5 mg day mouse starting 2 days 
after tumour cell inoculation. Treatment with EGCG inhibited tumor growth (58%), 
microvessel density (30%), and tumour cell proliferation (27%)) and increased tumour 
cell apoptosis (1.9-fold) and endothelial cell apoptosis (3-fold) relative to the control 
condition {P< 0.05 for all comparisons). EGCG may exert at least part of its 
anticancer effect by inhibiting angiogenesis through blocking the induction of VEGF 
(Fatima, Z., 2008). Tea polyphenol EGCG inhibits DNA methyltransferase and 
reactivates methylation-silenced genes in cancer cell lines (Barnes and Cave, 2003). 
Hyper-methylation of CpG islands in the promoter regions is an important mechanism 
to silence the expression of many important genes in cancer. Treatment of human 
esophageal cancer KYSE 510 cells with 5-50 microM of EGCG for 12-144 h caused a 
concentration- and time-dependent reversal of hypermethylation of pl6(INK4a), 
retinoic acid receptor beta (RARbeta), 0(6)-methylguanine methyltransferase 
(MGMT), and human mutL homologue 1 (hMLHl) genes as determined by the 
appearance of the unmethylation-specific bands in PCR. This was accompanied by the 
expression of mRNA of these genes as determined by reverse transcription-PCR 
(Zeeshan, 2008) thereby demonstrating for the first time the inhibition of DNA 
methylation by a commonly consumed dietary constituent and in turn suggesting for 
the potential use of EGCG for the prevention or reversal of related gene silencing in 
the prevention of carcinogenesis. In addition to this EGCG activates endothelial nitric 
oxide synthase by a PI3K-, PKA-, and Akt-dependent pathway, and leads to 
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endothelial-dependent vasorelaxation, the EGCG-induced endothelium-dependent 
vasodilation is primarily based on rapid activation of eNOS. This suggests that tea 
catechins may reduce the risk of cardiovascular (Zeeshan, 2008). Interleukin-1 beta 
(IL-lbeta) induced inflammatory response in arthritic joints include the enhanced 
expression and activity of matrix metalloproteinases (MMPs) and their matrix 
degrading activity contribute to the irreversible loss of cartilage and may also be 
associated with sustained chronic inflammation. EGCG inhibited the IL-1 beta-
induced mRNA and protein expression of MMP-1, and MMP-13 in human 
chondrocytes, a differential dose-dependent effect of EGCG on the expression and 
activity of MMPs and on the activities of transcription factors NF-kappaB and AP-1 
and provide insights into the molecular basis of the reported anti- inflammatory 
effects of EGCG (Zeeshan, 2008). It's well established that fruits and vegetables 
contain components like polyphenols, terpenes, alkaloids, and phenolics that may 
provide substantial health benefits beyond basic nutrition. Research over the last 
decade has shown that several micronutrients in fruits and vegetables reduce cancer 
(Aggarwal and Shishodia, 2006). The active components of dietary phytochemicals 
that most often appear to be protective against cancer are curcumin, genistein, 
resveratrol, diallyl sulfide, S-allyl cysteine, allicin, lycopene, capsaicin, diosgenin, 6-
gingerol, ellagic acid, ursolic acid, silymarin, anethol, catechins, eugenol, isoeugenol, 
dithiolthiones, isothiocyanates, indole-3-carbinol, isoflavones, protease inhibitors, 
saponins, phytosterols, inositol hexaphosphate, Vitamin C, d-limonene, lutein, folic 
acid, beta carotene, selenium, Vitamin E, flavonoids, and dietary fiber. These dietary 
agents are believed to suppress the inflammatory processes that lead to 
transformation, hyperproliferation, and initiation of carcinogenesis. Their inhibitory 
influences may ultimately suppress the final steps of carcinogenesis as well, namely 
angiogenesis and metastasis (Aggarwal and Shishodia, 2006). 
Various workers on cervical cancer HeLa cell lines have extensively carried 
out studies in multiple directions, but no or little work has been done on cervical 
cancer monocytes. Thus, the present study involves investigations on the effect of 
EGCG - a green tea polyphenol as well as a natural antioxidant on two cervical 
cancer model systems, which are: (a) monocytes and biopsies from cervical cancer 
patients and (b) cervical cancer cell lines i.e. HeLa cell lines. As the active role-
played by reactive oxygen species (ROS) in the cervical cancer is well established, 
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thus an attempt was made in the present study to probe natural compounds having 
antioxidant properties in arresting ROS in cancer cells. Thus, comparative efficacy of 
natural antioxidants was carried out on cervical cancer monocytes versus HeLa cell 
lines. 
The most striking finding of the present study is the model system involving 
monocytes and biopsies from cervical cancer patients showed high magnitude anti-
inflammatory as well as apoptotic effect of EGCG (0-100 |J.g/ml), while on the other 
hand, EGCG (0-100 i^g/ml) exerted high magnitude anti-inflammatory but low 
apoptotic effect on HeLa cell lines. Glutathione directly reacts with ROS. and GPx 
catalyzes the removal of hydrogen peroxide (Yokoigawa et al., 2005). Decrease in 
GPx activity indicates impairment of hydrogen peroxide-neutralizing mechanisms 
(Ottaviano et al., 2006). Co-culturing of cancerous (cervical) cells with NAC, 
turmeric or EGCG seems to induce apoptosis or acted as anti-inflammatory. 
Furthermore, apart from the above, a decline in GPx activity was observed in cervical 
cancer monocytes and cervical HeLa cells that were untreated or treated with H2O2 
thereby correlating with earlier reports that substantial amounts of ROS are being 
generated in cancerous cells due to cellular activation (Islam et al., 2004). 
Enhancement / amelioration of GPx activity in cervical cancer monocytes and 
cervical HeLa cell cultures after addition of NAC, a precursor of in vivo antioxidant 
glutathione, indicates reversal of impaired neutralizing mechanisms. Surprisingly, 
here augmented amelioration in GPx activity was observed when EGCG was co-
cultured instead of NAC, indicating EGCG to be an effective natural antioxidant 
combating ROS, generated as a consequence of cellular activation in cancerous cell. 
When compared to healthy monocytes, cervical cancer monocytes as well as HeLa 
cell lines exhibited an appreciable EGCG-mediated suppression by around 2.14-folds 
and 1.98-folds respectively in the GPx activity. On the contrary, upon co-culturing of 
cervical cancer monocytes and HeLa cell lines with varying doses of EGCG, an 
appreciable amelioration in the GPx activity was recorded. Interestingly, EGCG was 
found to possess a higher potential to ameliorate the GPx activity in cervical cancer 
monocytes than in HeLa cell lines. Similar were the observations recorded with NAC 
and turmeric. Furthermore, the present study shows enhanced GPx activity by EGCG, 
which correlated inversely with the downregulation of TNF-alpha, IL-1 and IL-6 
protein expressions and ROS in cervical cancerous cells. As suggested by (Aggarwal 
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and Shishodia, 2006) as well as by the present study, since, currently available 
modem medicines for treating cancers are very expensive, toxic, and less effective in 
treating the disease, thus, one must investigate further in detail the agents derived 
from natural sources, described traditionally, for the prevention and treatment of 
cancer and disease. Voluminous clinical trials are needed to validate the usefulness of 
these agents either alone or in combination with existing therapy. 
Although the chemopreventive effect of EGCG has been extensively studied 
by a number of workers in cancerous cell lines (Barnes and Cave, 2003; Ahn et al , 
2003; Wu et al , 2009) but its apoptotic effect and mechanism in biopsies and 
monocytes of cervical cancer patients still remains to be properly understood. Thus, in 
the present study, we show the mechanism of EGCG mediated apoptosis in 
monocytes of cervical cancer patients which involved activation of caspase-3, the 
executor of apoptosis and cleavage of PARP - a specific marker of apoptosis as well 
as suppression of IL-6. EGCG was highly effective in inhibiting the viability of 
cervical cancer monocytes by PARP cleavage in response to activation of caspase-3. 
This resulted in the loss of normal PARP function which irreversibly commits the cell 
to die (Bellosillo et al., 1998; Rukmini et al., 2004; Islam et al., 2000; Islam et al., 
2002). 
Apoptosis is one of the most investigated areas in carcinogenesis because of 
its wide-ranging implications and possible role in therapeutic interventions (Khan et 
al., 2006; Nihal et al., 2005). Caspases are recognized as key molecules in apoptotic 
response and are reflective of the protein alterations as consequence of apoptotic 
changes in cell. Apoptosis occurs via two major different activation pathways (Singh 
et al., 2002; Raff, 1998). One pathway involves changes in mitochondrial 
transmembrane potential, leading to the release of cytochrome c. Cytochrome c then 
binds the apoptosis activating factor 1 and procaspase-9, resulting in the activation of 
caspase-9 by proteolytic cleavage. The other pathway starts with death receptor 
ligation or Fas/FasL interaction, followed by oligomerization of the receptor, 
recruitment of Fas-associated death domain protein (FADD), and activation of 
caspase-8 (Gastman, 2001). Both caspase-9 and caspase-8 are defined as initiator 
caspases and can in turn activate caspase-3, the executor of apoptosis (Green, 1998; 
Green and Reed, 1998). Also, cross communication exists between the two pathways, 
107 
as caspase-8 may activate caspase-9 via Bid, a member of Bcl-2 family (Ashkenazi 
and Dixit, 1998). 
Our present study demonstrated the activities of caspase-3, caspase-8 and 
caspase-9 in cervical cancer monocytes were activated by EGCG, indicating that both 
death receptor-related apoptotic pathway and the mitochondria-related pathway were 
activated. On the contrary, suppression or reduction in cell viability was inhibited by 
inhibitors of caspase-3, 8 and 9 namely Z-VAD-FMK, Z-IETD-FMK and Z-LEHD-
FMK respectively, which specifically blocked PARP cleavage. 
We further observed that either specific caspase-8 or caspase-3 inhibitor 
blocked the EGCG-induced apoptosis by an appreciably high magnitude, whereas the 
caspase-9 inhibitor only partially inhibited it. This implies that apoptosis induced by 
EGCG in cervical cancer monocytes were initiated by a pathway involving the 
activation of caspase-8, leading to the activation of caspase-3 and the cleavage of 
PARP. The activation of caspase-9 is probably a secondary consequence of the 
activation of caspase-8 through the cross communication between the two apoptotic 
pathways (Islam et al., 2004; Stennicke, and Salvesen, 1998; Stennicke et al., 1998). 
Cytosmears from non-neoplastic ectocervical biopsy cultures with EGCG also 
showed only keratinization promoting effects of EGCG and no apoptotic cells could 
be seen. On the contrary, cytosmears from cervical cancer biopsy cultured with 
EGCG showed distinguished nuclear condensation and rounded contours with deep 
eosinophilia of cell cytoplasm, thereby indicating for EGCG-induced apoptotic. 
Histopathological sections from EGCG treated test samples also showed evidences of 
apoptosis, showing one apoptotic cell per 2-3 high power fields to more than one 
dispersed apoptotic cells in a single high power field. Occasionally, apoptotic cells 
were seen in groups implying foci of apoptotic changes. 
Next, we also report suppression of high levels of IL-6 in cultures of cervical 
cancer monocytes by EGCG to be dose-dependent. In accordance with its potential 
role in cancer progression, various types of cancer show elevated level of lL-6 (Orth. 
et al., 1996) and that, the strong ability of malignant cells to escape immune 
surveillance is a well known phenomenon. The anti-tumor immune response has been 
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reported to be regulated by several factors, which includes cytokines produced by 
tumor and other cells of tumor stroma. It seems likely that the local cytokine 
microenvironment, acting on tumor cell or on the adjacent cells, can either block or 
facilitate tumor growth, and that proinflammatory cytokines strongly influence the 
immunologic state (Orth et al., 1996). 
Treatment with EGCG increased the proportion of cells in the Gi phase of the cell 
cycle and induced apoptosis. The results in the present study indicated EGCG to 
decrease the anti-apoptotic Bcl-2 protein expression, and activation of caspase-3, 8 
and 9, suggesting that EGCG induces apoptosis via a both cellular as well as 
mitochondrial pathway, although the major pathway was cellular. Reports indicate 
that treatment with EGCG inhibited phosphorylation of the EGFR, signal transducer 
and activator of transcriptions (Stat3), and extracellular regulated kinase (ERK) 
proteins and also inhibited basal and transforming growth factor- a -stimulated c-fos 
and cyclin Dl promoter activity. EGCG at 0.1 |ig/ml (a concentration found in serum 
after oral administration) markedly enhanced the growth-inhibitory effects of 5-
fluorouracil. Taken together, the findings of the present study as well as by other 
workers (Liao et al., 2004; Schuller et al., 2004; Lu et al., 2006) provide insights into 
molecular mechanisms of grov^h inhibition by EGCG. Furthermore, reports also 
indicate that EGCG inhibited growth and induced apoptosis in human prostate, lung, 
colon, and gastric carcinoma and human leukemia cancer cell lines (Yang et al., 2005; 
Ju et al., 2005; Siddiqui et al , 2006; Roomi et al., 2005). Studies with EGCG in some 
cell types indicated that it could inhibit signaling pathways related to the activation of 
growth factor receptors. HNSCCs often display up-regulation of TGF- a/EGFR signal 
transduction pathways, (Stat3 lies downstream of the TGF- a/EGFR signaling 
pathway, and StatS is strongly implicated in the growth of these carcinomas and in 
protecting them from apoptosis. 
The observations made in the present study demonstrate that EGCG, a major 
component of green tea, possesses cervical cancer cell growth inhibitory properties. It 
is likely that EGCG inhibits cancer cell growth through many different regulatory 
pathways, along with apoptosis and cell cycle arrest. The results of the present study 
are consistent with EGCG inhibiting cell growth and iaduciug apoptosis w. c^ivical 
cancer biopsies and HeLa cell lines. The cytotoxic properties of EGCG seemed to be 
more effective against cervical cancer monocytes than HeLa cells. At this time, there 
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is no explanation for these differences and more experiments are needed for further 
analysis. The induction of apoptotic cell death by EGCG was accompanied by 
characteristic morphological and structural changes as well as intemucleosomal DNA 
degradation. PARP-cleavage and FITC-Annexin assays in the present study clearly 
confirmed apoptosis induction in EGCG-treated cervical cancer cells. As per the 
manual supplied by the manufacturer of FITC-Annexin assay kit, apoptosis is a 
normal physiologic process, which occurs during embryonic development as well as 
in maintenance of tissue homeostasis. Certain morphologic features, including loss of 
plasma membrane asymmetry and attachment, condensation of the cytoplasm and 
nucleus, and intemucleosomal cleavage of DNA, characterize the apoptotic program. 
Loss of plasma membrane is one of the earliest features. In apoptotic cells, the 
membrane phospholipid phosphatidylserine (PS) is translocated from the inner to the 
outer leaflet of the plasma membrane, thereby exposing PS to the external cellular 
environment. Annexin V is a 35-36 kDa Ca2+ dependent phospholipid-binding 
protein that has a high affinity for PS, and binds to cells with exposed PS. Annexin V 
may be conjugated to fluorochromes including FITC. This format retains its high 
affinity for PS and thus serves as a sensitive probe for flow cytometric analysis of 
cells that are undergoing apoptosis. Since extemalization of PS occurs in the earlier 
stages of apoptosis, FITC Annexin V staining can identify apoptosis at an earlier stage 
than assays based on nuclear changes such as DNA fragmentation. FITC Annexin V 
staining precedes the loss of membrane integrity which accompanies the latest stages 
of cell death resulting from either apoptotic or necrotic processes. Therefore, staining 
with FITC Annexin V is typically used in conjunction with a vital dye such as 
propidium iodide (PI) or 7-Amino-Actinomycin (7-AAD) to allow to identify early 
apoptotic cells (PI negative, FITC Annexin V positive). Viable cells with intact 
membranes exclude PI, whereas the membranes of dead and damaged cells are 
permeable to PI. For example, cells that are considered viable are FITC Annexin V 
and PI negative; cells that are in early apoptosis are FITC Annexin V positive and PI 
negative; and cells that are in late apoptosis or already dead are both FITC Annexin V 
and PI positive. This assay does not distinguish between cells that have undergone 
apoptotic death versus those that have died as a result of a necrotic pathway because 
in either case, the dead cells will stain with both FITC Annexin V and PI. However, 
when apoptosis is measured over time, cells can be often tracked from FITC Annexin 
V and PI negative (viable, or no measurable apoptosis), to FITC Annexin V positive 
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and PI negative (early apoptosis, membrane integrity is present) and finally to FITC 
Annexin V and PI positive (end stage apoptosis and death). The movement of cells 
through these three stages suggests apoptosis. In contrast, a single observation 
indicating that cells are both FITC Aimexin V and PI positive, in of itself, reveals less 
information about the process by which the cells underwent their demise. Apoptosis is 
a tightly regulated process which involves changes in the expression of distinct genes. 
One group of genes regulating apoptosis are cytoplasmic aspartate specific cysteine 
proteases of the ICE/CED-3 family, better knovm as caspases (Klaus et al, 1998). 
Caspase-3, for example, inactivates poly (ADP-ribosyl) polymerase by proteolytically 
degrading the 116 kDa enzyme into an 85 kDa fragment (Duriez and Shah, 1997; Li 
and Darzynkiewicz, 2000; Nigata, 2000). When cervical cancer monocytes were 
treated with EGCG, the expression level of procaspase-3 was decreased (data not 
shown) indicating that the active form of caspase-3 was generated. It is therefore 
inferred that EGCG-induced apoptotic death in cervical cancer monocytes was 
mediated in part by activation of caspase-3. 
In summary, EGCG, a natural antioxidant, is a potent inducer of apoptosis in 
monocytes, biopsies of cervical cancer patients as well as HeLa cell lines, and that, 
induction of EGCG-mediated apoptosis involved activation of caspase-3 / CPP32, 
caspase-8 and caspase-9 as well as IL-6 suppression. The apoptotic as well as anti-
inflammatory / anti-proliferative effects of EGCG was more prominent in cervical 
cancer monocytes than in HeLa cell lines. Why EGCG is more effective in cervical 
cancer monocytes than in HeLa cell lines warrants further in-depth investigation. It is 
hoped that in view of the above aspects, whether EGCG can be promising candidate 
for the chemoprevention of cervical cancer might be an interesting topic for further 
investigation. 
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